---
title: "Grotenhermen 2003 Pharmacokinetics cannabinoids"
source: "Grotenhermen_2003_Pharmacokinetics_cannabinoids.pdf"
converted: "2026-01-25"
pages: 34
---

# Pharmacokinetics and
# Pharmacodynamics of Cannabinoids
Franjo Grotenhermen
Nova-Institut, Hürth, Germany
Contents
Abstract
.  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  . 328
1. Taxonomy  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  . 329
2. Physicochemical Properties and Degradation of Dronabinol  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  . 330
3. Pharmacokinetics of Δ9-Tetrahydrocannabinol  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  . 330
3.1
Absorption  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  . 331
3.1.1 Inhalation  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  . 331
3.1.2 Oral Administration .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  . 331
3.1.3 Ophthalmic Administration  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  . 332
3.1.4 Rectal Administration  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  . 332
3.1.5 Sublingual Administration  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  . 333
3.1.6 Dermal Administration  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  . 333
3.2
Distribution .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  . 333
3.2.1 Distribution to Tissues  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  . 334
3.2.2 Distribution to Fetus and Breast Milk  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  . 335
3.3
Metabolism  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  . 335
3.4
Time Course of Plasma Concentration of Δ9-Tetrahydrocannabinol
and Metabolites  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  . 336
3.5
Elimination  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  . 336
3.5.1 Elimination from Plasma  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  . 336
3.5.2 Excretion with Urine and Faeces  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  . 338
3.6
Time–Effect Relationship  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  . 339
3.6.1 Correlation of Time and Effects .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  . 339
3.6.2 Pharmacokinetic-Pharmacodynamic Modelling  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  . 340
3.6.3 Predicting Time of Use  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  . 341
3.7
Pharmacokinetics of Other Cannabinoids  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  . 341
3.7.1 Cannabidiol .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  . 341
3.7.2 Nabilone .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  . 341
3.7.3 Dexanabinol  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  . 341
3.7.4 Metabolic Interaction of Cannabinoids  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  . 341
4. Pharmacodynamics  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  . 342
4.1
Mechanism of Action  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  . 342
4.1.1 Cannabinoid Receptors  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  . 342
4.1.2 Endocannabinoids  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  . 343
4.1.3 Affinity for the Cannabinoid Receptor .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  . 343
4.1.4 Tonic Activity of the Endocannabinoid System .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  . 343
4.2
Pharmacological Effects of Δ9-Tetrahydrocannabinol .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  . 343
4.2.1 Toxicity  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  . 344
4.2.2 Psyche, Cognition and Behaviour  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  . 345
4.2.3 Central Nervous System and Neurochemistry  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  . 345
DRUG DISPOSITION
Clin Pharmacokinet 2003; 42 (4): 327-360
0312-5963/03/0004-0327/$30.00/0
© Adis International Limited. All rights reserved.

4.2.4 Circulatory System  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  . 345
4.3
Effects on Some Other Organ Systems .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  . 345
4.3.1 Antibacterial and Antiviral Actions .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  . 345
4.3.2 Eye  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  . 345
4.3.3 Hormonal System and Fertility .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  . 346
4.3.4 Genetics and Cell Metabolism  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  . 346
4.3.5 Immune System  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  . 346
4.3.6 Sperm  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  . 346
4.3.7 Digestive Tract  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  . 346
4.4
Pharmacological Activity of Δ9-Tetrahydrocannabinol Metabolites .  .  .  .  .  .  .  .  .  .  .  .  .  .  . 346
4.4.1 11-Hydroxy-Δ9-Tetrahydrocannabinol  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  . 346
4.4.2 11-Nor-9-Carboxy-Δ9-Tetrahydrocannabinol  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  . 346
4.5
Pharmacological Effects of Other Cannabinoids  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  . 346
4.5.1 Phytocannabinoids  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  . 346
4.5.2 Endocannabinoids  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  . 347
4.5.3 Classical Synthetic Cannabinoids  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  . 347
4.5.4 Nonclassical Synthetic Cannabinoids  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  . 347
4.5.5 Anandamide Analogues  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  . 348
4.5.6 Therapeutic Potential of Antagonists  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  . 348
5. Tolerance and Dependency  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  . 348
5.1
Tolerance  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  . 348
5.2
Withdrawal and Dependency  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  . 349
6. Therapeutic Uses  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  . 349
6.1
Hierarchy of Therapeutic Effects  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  . 349
6.2
Established Effects  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  . 349
6.3
Relatively Well-Confirmed Effects .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  . 349
6.4
Less Confirmed Effects  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  . 349
6.5
Basic Research Stage  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  . 350
7. Drug Interactions  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  . 350
8. Conclusions  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  . 350
Abstract
Δ9-Tetrahydrocannabinol (THC) is the main source of the pharmacological
effects caused by the consumption of cannabis, both the marijuana-like action
and the medicinal benefits of the plant. However, its acid metabolite THC-COOH,
the non-psychotropic cannabidiol (CBD), several cannabinoid analogues and
newly discovered modulators of the endogenous cannabinoid system are also
promising candidates for clinical research and therapeutic uses. Cannabinoids
exert many effects through activation of G-protein-coupled cannabinoid recep-
tors in the brain and peripheral tissues. Additionally, there is evidence for non-
receptor-dependent mechanisms.
Natural cannabis products and single cannabinoids are usually inhaled or taken
orally; the rectal route, sublingual administration, transdermal delivery, eye drops
and aerosols have only been used in a few studies and are of little relevance in
practice today. The pharmacokinetics of THC vary as a function of its route of
administration. Pulmonary assimilation of inhaled THC causes a maximum
plasma concentration within minutes, psychotropic effects start within seconds
to a few minutes, reach a maximum after 15–30 minutes, and taper off within
2–3 hours. Following oral ingestion, psychotropic effects set in with a delay of
30–90 minutes, reach their maximum after 2–3 hours and last for about 4–12
hours, depending on dose and specific effect.
328
Grotenhermen
© Adis International Limited. All rights reserved.
Clin Pharmacokinet 2003; 42 (4)

At doses exceeding the psychotropic threshold, ingestion of cannabis usually
causes enhanced well-being and relaxation with an intensification of ordinary
sensory experiences. The most important acute adverse effects caused by over-
dosing are anxiety and panic attacks, and with regard to somatic effects increased
heart rate and changes in blood pressure. Regular use of cannabis may lead to
dependency and to a mild withdrawal syndrome. The existence and the intensity
of possible long-term adverse effects on psyche and cognition, immune system,
fertility and pregnancy remain controversial. They are reported to be low in hu-
mans and do not preclude legitimate therapeutic use of cannabis-based drugs.
Properties of cannabis that might be of therapeutic use include analgesia,
muscle relaxation, immunosuppression, sedation, improvement of mood, stimu-
lation of appetite, antiemesis, lowering of intraocular pressure, bronchodilation,
neuroprotection and induction of apoptosis in cancer cells.
The chemical structure of the first phyto-
cannabinoids was successfully characterised in the
1930s and 1940s,[1] but it was not until 1964 that
the chemical structure of Δ9-tetrahydrocannabinol
(Δ9-THC), mainly responsible for the pharmaco-
logical effects of the cannabis plant,[2,3] had been
identified and synthesised.[4] Another scientific
breakthrough in cannabinoid research has been the
detection of a system of specific cannabinoid re-
ceptors in mammals[5] and their endogenous
ligands[6] within the past 15 years.
1. Taxonomy
Originally, the term cannabinoid referred to the
phytocannabinoids of Cannabis sativa L. with a
typical C21 structure and their transformation prod-
ucts,[7] but this restricted pharmacognostic defini-
tion has been discarded in favour of a broader
concept based on pharmacology and synthetic
chemistry.[8] Today the term cannabinoid may
comprise all ligands of the cannabinoid receptor
and related compounds, including endogenous
ligands of the receptors and a large number of syn-
thetic cannabinoid analogues.
The phytocannabinoids have been numbered
according to the monoterpenoid system or the
dibenzopyran system (figure 1); the latter system
will be employed in this review. A total of 66 phy-
tocannabinoids have been identified, most of them
belonging to several subclasses or types:[9] the can-
nabigerol (CBG), cannabichromene (CBC), can-
nabidiol (CBD), Δ9-THC, Δ8-THC, cannabicyclol
(CBL), cannabielsoin (CBE), cannabinol (CBN),
cannabinodiol (CBDL) and cannabitriol (CBTL)
types. A total of nine cannabinoids belong to the
Δ9-THC group, with side chains of one, three, four
and five carbons (figure 2 and table I).
The cannabinoid acids of Δ9-THC, CBD, CBC
and CBG are the quantitatively most important
cannabinoids present in the plant (see table II and
figure 3). Their relative concentrations vary, and
plants have been described that mainly contain one
of these cannabinoids with a C5 side chain or con-
tain the propyl homologue (C3 side chain) of Δ9-
THC (Δ9-trans-tetrahydrocannabivarin);[10-12] the
methyl (C1 side chain) and butyl (C4 side chain)
homologues are always present in very low con-
centrations.[13,14]
The cannabinoid acids of THC are devoid of
psychotropic effects[2] and have to be decarboxyl-
ated to the phenols to produce marijuana-like ef-
fects, e.g. by smoking the dried plant matter. The
ratio of Δ9-THC acids to phenolic Δ9-THC has been
reported to range between 2 : 1[11] and >20 : 1[16]
in leaves and flowers of Cannabis sativa. In plants
grown in the United Kingdom from Moroccan, Sri
Lankan and Zambian seed stock, the Δ9-THC
acids/Δ9-THC ratio was 17 : 1 compared with 2 : 1
in the plants from the original areas with hotter
climates.[11] In cannabis resin (hashish), the THC
acids/THC ratio was reported to range between
6.1 : 1 and 0.5 : 1.[17]
Cannabinoids
329
© Adis International Limited. All rights reserved.
Clin Pharmacokinet 2003; 42 (4)

Natural Δ9-THC has two chiral centres at C-6a
and C-10a in the trans configuration. Usually the
acronym THC is applied to this naturally occurring
(–)-trans-isomer of Δ9-THC, and will be used in
this text as well. The generic name for Δ9-trans-
tetrahydrocannabinol is dronabinol. Marinol™1
(Unimed Pharmaceuticals, Inc.) contains synthetic
dronabinol, dissolved in sesame oil, as capsules of
2.5, 5 and 10mg of dronabinol.
2. Physicochemical Properties and
Degradation of Dronabinol
THC and many of its metabolites are highly li-
pophilic and essentially water-insoluble.[18] Calcu-
lations of the n-octanol/water partition coefficient
(Kow) of THC at neutral pH vary between 6000
using shake-flask methodology[19] and 9 440 000
by reverse-phase high-pressure liquid chromato-
graphic estimation.[20] The wide range for aqueous
solubility and Kow, can be attributed to the diffi-
culty of uniformly dissolving this essentially
water-insoluble substance and accurately measur-
ing small amounts of it. The spectrophotometric
pKa is 10.6.[18]
THC is thermolabile and photolabile.[21,22] Stor-
age leads to a cumulative decrease in THC content
through oxidation of THC to CBN.[23,24] Within 47
weeks, the THC content of marijuana (dried leaves
and flowers of Cannabis sativa) decreased by 7%
with dark and dry storage at 5°C, and by 13% at
20°C.[24] Dronabinol rapidly degrades in acid so-
lutions. The kinetics seem to be first order and spe-
cifically hydrogen ion-catalysed,[18] so that signif-
icant degradation is assumed to occur in the normal
stomach with a half-life of 1 hour at pH 1.[18]
Decarboxylation of the THC acids to the corre-
sponding phenols occurs readily over time, upon
heating[16,23] or under alkaline conditions. Heating
for 5 minutes at a temperature of 200–210°C has
been reported to be optimal for this purpose,[16] but
a few seconds in burning cannabis cigarettes are
equally sufficient. Slow decarboxylation of THC
acid occurs at room temperature.
3. Pharmacokinetics of
Δ9-Tetrahydrocannabinol
Cannabis products are commonly either inhaled
by smoking a cannabis cigarette, taken orally as
dronabinol capsules or in baked foods or liquids
O
OH
7
1
2
3
1'
2'
3'
4'
5"
3"
1"
5'
6'
8
9
10
4
5
6
Monoterpenoid numbering
O
OH
11
9
10
10a
10b
1
2
3
5'
3'
1'
4
5
6
12
13
6a
7
8
Dibenzopyran numbering
Fig. 1. Chemical structure of tetrahydrocannabinol (THC), the main cannabinoid in the cannabis plant, numbered according to the
monoterpenoid system (Δ1-THC) and dibenzopyran system (Δ9-THC).
1 Use of tradenames is for product identification only and
does not imply endorsement.
OH
O
R3
R2
R1
Fig. 2. Cannabinoids of the Δ9-tetrahydrocannabinol (THC) type.
The most widespread cannabinoids are the phenolic Δ9-THCs
with 21 carbon atoms and a C5 side chain (R2 = C5H11) and its
two corresponding carboxylic acids A and B with R1 or R3 =
COOH (see table I).
330
Grotenhermen
© Adis International Limited. All rights reserved.
Clin Pharmacokinet 2003; 42 (4)

(figure 4). Various other routes of administration
and delivery forms have been tested for therapeutic
purposes. The rectal route with suppositories has
been applied in some patients,[25] and dermal[26]
and sublingual[27] administration are under inves-
tigation. Other methods include eye drops to de-
crease intraocular pressure,[28] as well as aerosols
and inhalation with vaporisers to avoid the harm
associated with smoking.[29,30] The kinetics of can-
nabinoids are much the same for females and
males,[31] as well as for frequent and infrequent
users.[32,33]
3.1 Absorption
3.1.1 Inhalation
THC is detectable in plasma only seconds after
the first puff of a cannabis cigarette[35] with peak
plasma concentrations being measured 3–10 min-
utes after onset of smoking (figure 5).[35-40] Sys-
temic bioavailability generally ranges between
about 10 and 35%, and regular users are more ef-
ficient (table III).[38] Bioavailability varies accord-
ing to depth of inhalation, puff duration and
breathhold.
A systemic bioavailability of 23 ± 16%[38] and
27 ± 10%[42] for heavy users versus 10 ± 7% and
14 ± 1% for occasional users of the drug was re-
ported. In a study with a smoking machine, pat-
terns of cannabis smoking were simulated with re-
gard to puff duration and volume,[43] resulting in
16 to 19% of THC in the mainstream smoke. If the
whole cigarette was smoked in one puff the per-
centage of THC in the mainstream increased to
69%. About 30% is assumed to be destroyed by
pyrolysis. With smoking, additional THC is lost in
the butt, in sidestream smoke, and by incomplete
absorption in the lungs. Smoking a pipe that pro-
duces little sidestream smoke may also result in
high effectiveness, with 45% of THC transferred
via the mainstream smoke in one smoker tested.[23]
3.1.2 Oral Administration
With oral use, absorption is slow and erratic,
resulting in maximal plasma concentrations usu-
ally after 60–120 minutes (figure 6).[31,39,44] In sev-
eral studies, maximal plasma concentrations were
observed as late as 4 hours[45] and even 6 hours in
some cases.[39,41,46] Several subjects showed more
than one plasma peak.[37,39,41]
Table I.  Cannabinoids of the Δ9-trans-tetrahydrocannabinol type
Cannabinoid
R1a
R2
R3
Δ9-trans-Tetrahydrocannabinolic acid A
COOH
C5H11
H
Δ9-trans-Tetrahydrocannabinolic acid B
H
C5H11
COOH
Δ9-trans-Tetrahydrocannabinol
H
C5H11
H
Δ9-trans-Tetrahydrocannabinolic acid-C4
COOH or H
C4H9
H or COOH
Δ9-trans-Tetrahydrocannabinol-C4
H
C4H9
H
Δ9-trans-Tetrahydrocannabivarinic acid
COOH
C3H7
H
Δ9-trans-Tetrahydrocannabivarin
H
C3H7
H
Δ9-trans-Tetrahydrocannabiorcolic acid
COOH or H
CH3
H or COOH
Δ9-trans-Tetrahydrocannabiorcol
H
CH3
H
a
See figure 2 for the basic chemical structure of Δ9-trans-tetrahydrocannabinol.
Table II. Average cannabinoid concentrations in 35 312 cannabis preparations confiscated in the US between 1980 and 1997[15]
THC (%)
CBD (%)
CBC (%)
CBN (%)
Marijuana
3.1
0.3
0.2
0.3
Sinsemilla
8.0
0.6
0.2
0.2
Hashish
5.2
4.2
0.4
1.7
Hashish oil
15.0
2.7
1.1
4.1
CBC = cannabichromene; CBD = cannabidiol; CBN = cannabinol; THC = Δ9-tetrahydrocannabinol.
Cannabinoids
331
© Adis International Limited. All rights reserved.
Clin Pharmacokinet 2003; 42 (4)

Δ9-THC is expected to be degraded by the acid
of the stomach and in the gut.[18] At low pH,
isomerisation to Δ8-THC and protonation of the oxy-
gen in the pyran ring may occur with cleavage to
substituted CBDs.[18] It has been suggested that a
somewhat higher bioavailability is obtained in an
oil formulation.[47] However, absorption seems to
be nearly complete in different vehicles. Ninety-
five percent of total radioactivity of radiolabelled
THC was absorbed from the gastrointestinal tract
in an oil vehicle[31] and 90–95% if taken in a cherry
syrup vehicle,[48]  but it is unclear from these data
how much of this radioactivity belongs to un-
changed THC and how much to breakdown prod-
ucts.
An extensive first-pass liver metabolism further
reduces the oral bioavailability of THC, i.e. much
of the THC is initially metabolised in the liver be-
fore it reaches the sites of action. Ingestion of THC
20mg in a chocolate cookie[39] and administration
of dronabinol 10mg[41] resulted in a very low sys-
temic bioavailability of 6 ± 3% (range 4–12%)[39]
or 7 ± 3% (range 2–14%),[41] respectively, with a
high interindividual variation.
3.1.3 Ophthalmic Administration
A study in rabbits with THC in light mineral oil
determined a variable systemic bioavailability of
6–40% with ophthalmic administration.[49] Plasma
concentrations peaked after 1 hour and remained
high for several hours.
3.1.4 Rectal Administration
With rectal application, systemic bioavailabil-
ity strongly differed depending on suppository for-
mulations. Among formulations containing several
polar esters of THC in various suppository bases,
THC-hemisuccinate in Witepsol H15 showed the
highest bioavailability in monkeys and was calcu-
R3O
OH
R1
R2
O
OH
R1
R2
OH
R1
R2
O
R3
O
OR1
R2
R3
R1 = H or COOH
R2 = C3 or C5 side chain
R3 = H or CH3
Cannabigerol type
R1 = H or COOH
R2 = C3 or C5 side chain
Cannabichromene type
R1 = H or COOH
R2 = C1, C3, C4, or C5 side chain
R3 = H or CH3
Cannabidiol type
R1 = H or C3
R2 = H or COOH
R3 = C1, C3, C4, or C5 side chain
Cannabinol type
Fig. 3. Some phytocannabinoids.
332
Grotenhermen
© Adis International Limited. All rights reserved.
Clin Pharmacokinet 2003; 42 (4)

lated to be 13.5%.[50] The rectal bioavailability of
this formulation was calculated to be about as
twice as high as oral bioavailability in a small clin-
ical study.[25]
3.1.5 Sublingual Administration
Clinical studies are under way using a liquid
cannabis extract applied under the tongue. A phase
I study in six healthy volunteers receiving up to
20mg of THC was reported to result in ‘relatively
fast’ effects.[27] In phase II studies, THC plasma
concentrations of up to 14 μg/L were noted.[51]
3.1.6 Dermal Administration
In a study using the more stable Δ8-THC isomer,
the permeability coefficient of THC was signifi-
cantly enhanced by water and by oleic acid in pro-
pylene glycol and ethanol,[52] resulting in signifi-
cant THC concentrations in the blood of rats.
Studies designed to develop transdermal delivery
of cannabinoids found a mean effective permeabil-
ity coefficient for Δ9-THC in propylene glycol of
6.3 × 10–6 cm/h.[26]
3.2 Distribution
Tissue distribution of THC and its metabolites
is assumed to be governed only by their physico-
chemical properties, with no specific transport
processes or barriers affecting the concentration of
the drug in the tissues.[53]
About 90% of THC in the blood is distributed
to the plasma, another 10% to red blood cells.[54]
95–99% of plasma THC is bound to plasma pro-
teins, mainly to lipoproteins and less to albu-
min.[32,54-56]
The time course of plasma concentrations of
cannabinoids has been described to fit to open
two-compartment,[31,57] three-compartment[44,58,59]
or four-compartment[32] models. Even five- and
six-compartment models have been found in com-
puter models to best fit the THC plasma course in
animals.[53]
Serum protein binding
Lipoproteins, albumin
Tissue storage
Fat, protein
Hair, saliva, sweat
THC concentration in extracellular water
Absorption
THC concentration at site of action
Metabolism
Hepatic microsomal,
non-microsomal,
extrahepatic
Metabolites
Biliary excretion
Enterohepatic recirculation
Renal excretion
Glomerular filtration,
tubular secretion,
passive reabsorption
Lung, intestine, colon, skin
Administration
THC
Cannabinoid receptors,
other targets of action
THC effects
Fig. 4. Pharmacokinetic properties of Δ9-tetrahydrocannabinol (THC) [reproduced from Brenneisen[34] with permission].
Cannabinoids
333
© Adis International Limited. All rights reserved.
Clin Pharmacokinet 2003; 42 (4)

The apparent (initial) volume of distribution of
THC is small for a lipophilic drug, equivalent to
the plasma volume of about 2.5–3L, reflecting high
protein binding that complicates initial disposition.
It was reported to be 2.55 ± 1.93L in drug-free
users[32] and 6.38 ± 4.1L in regular users.[32] The
steady-state volume of distribution has been esti-
mated to be more than 100 times larger, in the
range of about 10 L/kg.[31,32,57] These early data
have been questioned because of the possible inac-
curacy of the quantification methods used. Based
on pharmacokinetic data of two studies that used
gas chromatography-mass spectrometry (GC-MS)
for analysis of THC concentration, an average vol-
ume of distribution of 236L (or 3.4 L/kg assuming
70kg bodyweight) has been calculated.[60] Even
smaller steady-state volumes of distribution of
about 1 L/kg have been reported using GC-MS.[33]
This volume is still about 20 times the plasma vol-
ume, since the majority of the lipophilic drug is in
the tissues.
3.2.1 Distribution to Tissues
The lipophilicity of THC with high binding to
tissue and in particular to fat causes a change of
distribution pattern over time.[61] THC rapidly pen-
etrates highly vascularised tissues, among them
liver, heart, fat, lung, jejunum, kidney, spleen,
mammary gland, placenta, adrenal cortex, muscle,
thyroid and pituitary gland, resulting in a rapid de-
crease in plasma concentration.[62] Only about 1%
of THC administered intravenously is found in the
brain at the time of peak psychoactivity.[63] The
relatively low concentration in the brain is proba-
bly due to high perfusion rate of the brain moving
THC in and out of the brain rapidly.[64] Penetration
of the metabolite 11-hydroxy-Δ9-tetrahydrocan-
nabinol (11-OH-THC) into the brain seems to be
faster and higher than that of the parent com-
pound.[63,65] Thus, it can be expected that 11-OH-
0
20
40
60
80
100
120
140
160
180
Time during and after smoking (h)
Concentration (μg/L)
6
5
4
3
2
1
0
THC
11-OH-THC
THC-COOH
Fig. 5. Mean plasma concentrations of Δ9-tetrahydrocannabinol
(THC), 11-hydroxy-THC (11-OH-THC) and 11-nor-9-carboxy-
THC (THC-COOH) of six subjects during and after smoking a
cannabis cigarette containing about 34mg of THC.[35]
Table III. Systemic bioavailability of Δ9-tetrahydrocannabinol (THC)
Subjects
Systemic bioavailability (%)
Formulation
Reference
average
range
Oral
11 frequent or infrequent users
6 ± 3
4–12
THC in chocolate cookie
39
6 men, 6 women
10-20
THC in sesame oil
31
7 men, 10 women
7 ± 3
2–14
THC in sesame oil
41
Inhalational
9 heavy users
23 ± 6
6–56
Marijuana cigarette
38
9 light users
10 ± 7
2–22
Marijuana cigarette
38
5 heavy users
27 ± 10
16–39
Marijuana cigarette
42
4 light users
14 ± 1
13–14
Marijuana cigarette
42
11 frequent or infrequent users
18 ± 6
8–24
THC in cigarette
39
Rectal
2 patients with spasticity
190–220% of oral
bioavailability
Suppository with
THC-hemisuccinate
25
334
Grotenhermen
© Adis International Limited. All rights reserved.
Clin Pharmacokinet 2003; 42 (4)

THC will significantly contribute to the overall
central effects of THC, especially with oral use.
Subsequently, intensive accumulation occurs in
less vascularised tissues and finally in body fat,[66-68]
the major long-term storage site, resulting in con-
centration ratios between fat and plasma of up to
104 : 1.[69] The exact composition of the material
accumulated in fat is unknown,[47] among them
being unaltered THC and its hydroxy metabo-
lites.[68] A substantial proportion of the deposit in
fat seems to consist of fatty acid conjugates of 11-
OH-THC.[70,71]
3.2.2 Distribution to Fetus and Breast Milk
In animals and humans, THC rapidly crosses
the placenta.[72] The course of THC concentrations
in fetal blood closely approximates that in the ma-
ternal blood, though fetal plasma concentrations
were found to be lower than maternal concentra-
tions in several species.[73-76] The metabolites 11-
OH-THC and 11-nor-9-carboxy-Δ9-tetrahydro-
cannabinol (THC-COOH) cross the placenta much
less efficiently than THC.[74,76] Following oral in-
take, THC plasma concentrations in the fetus are
about one-tenth of the maternal plasma concentra-
tion.[75] In comparison, the fetal concentration is
about one-third of the maternal plasma concentra-
tion after intravenous or inhaled THC.[73,76] Thus,
oral intake may have less effect on the fetus com-
pared with inhalation. A study with dizygotic
twins demonstrated that the placenta plays a major
role in the variability of fetal exposure to can-
nabinoids.[77]
THC passes into the breast milk. In monkeys,
0.2% of the THC ingested by the mother appeared
in the milk.[78] Long-term administration leads to
accumulation.[79] In a human female, the THC con-
centration in milk was 8.4 times higher than in
plasma, in the low μg/L range.[79] Thus, a nursing
infant might ingest daily THC amounts in the
range of about 0.01–0.1mg from the milk of a
mother who is consuming one or two cannabis cig-
arettes a day.
3.3 Metabolism
Metabolism of THC occurs mainly in the liver
by microsomal hydroxylation and oxidation cata-
lysed by enzymes of the cytochrome P450 (CYP)
complex;[80,81] a member of the CYP2C subfamily
of isoenzymes plays the major role in humans.[82]
In rats, more than 80% of intravenous THC was
metabolised within 5 minutes.[83]
Metabolic rates show relevant interspecies dif-
ferences[84,85] that may be attributed to different
profiles of CYP isoenzymes.[85] This fact may be
in part responsible for some problems of interspe-
cies extrapolation of pharmacological and toxico-
logical effects.[86] In humans, allylic oxidation,
epoxidation, aliphatic oxidation, decarboxylation
and conjugation have been described.[64]
Nearly 100 metabolites have been identified for
THC.[85] Besides the liver, other tissues are also
able to metabolise cannabinoids but to a much
lesser degree, among them the heart and the
lung.[87-89]
Major metabolites are monohydroxylated com-
pounds. In humans[90,91] and many other spe-
cies,[85,87] C-11 is the major site attacked (figure
7). Hydroxylation results in 11-OH-THC and fur-
ther oxidation in THC-COOH, which may be
0
5
10
15
20
25
30
35
40
45
50
55
60
Time after oral ingestion (h)
Concentration (μg/L)
0
2
4
6
8
10
12
THC
11-OH-THC
THC-COOH
Fig. 6. Mean plasma concentrations of Δ9-tetrahydrocannabinol
(THC), 11-hydroxy-THC (11-OH-THC) and 11-nor-9-carboxy-
THC (THC-COOH) of six cancer patients after ingestion of one
oral dose of THC 15mg (estimated from single graphs for each
patient of Frytak et al.,[46] with permission). The plasma courses
of THC showed considerable interindividual variation (see figure
8 for the individual courses of THC plasma concentrations of
three patients).
Cannabinoids
335
© Adis International Limited. All rights reserved.
Clin Pharmacokinet 2003; 42 (4)

glucuronidated to 11-nor-9-carboxy-THC glucu-
ronide. Long-chain fatty acid conjugates of 11-
OH-THC are proposed to be a form in which THC
may be stored within tissues.[92] The C-8 position
is also attacked in humans but to a much lesser
degree than C-11.[91]
Average plasma clearance rates have been re-
ported to be 11.8 ± 3.0 L/h (197 ± 50 ml/min) for
women and 14.9 ± 3.7 L/h (248 ± 62 ml/min) for
men,[31] whereas others have determined higher
mean clearance rates of about 36 L/h (600 ml/min)
for naive THC users and about 60 L/h (1000
ml/min) for regular users (see table IV).[32] The
latter values are similar to the volume of hepatic
blood flow,[32,42] indicating that the limiting step
of the metabolic rate is controlled by hepatic blood
flow. These high clearance rates explain the high
degree of first-pass metabolism and the much
higher concentration of 11-OH-THC after oral ad-
ministration compared with inhalation.
3.4 Time Course of Plasma Concentration of
Δ9-Tetrahydrocannabinol and Metabolites
Intravenous infusion of THC 5mg within 2 min-
utes caused average plasma concentrations at 2
minutes after the end of infusion of 438 μg/L in
frequent and of 386 μg/L in infrequent users, that
fell rapidly to an average of 25 and 20 μg/L at 90
minutes.[33]
The course of plasma THC concentrations after
inhalation resembles that after intravenous admin-
istration.[35,40] Smoking a single cannabis cigarette
containing about 16 or 34mg of THC caused aver-
age peak concentrations of 84.3 μg/L (range 50.0–
129.0 μg/L) for the lower dose and 162.2 μg/L
(range 76.0–267.0 μg/L) for the higher dose, then
rapidly decreased to low concentrations of about
1–4 μg/L within 3–4 hours (figure 5).[35]
The maximal THC plasma concentration after
smoking a marijuana cigarette (3.55% THC) was
reported to exceed the maximal THC-COOH con-
centration by 3-fold and the maximal 11-OH-THC
concentration by 20-fold.[35] However, THC/11-
OH-THC ratios declined and reached a ratio of
about 2 : 1 after 2–3 hours.[35] Peak concentrations
for THC were observed 8 minutes (range 6–10
minutes) after onset of smoking, whereas 11-OH-
THC peaked at 15 minutes (range 9–23 minutes)
and THC-COOH at 81 minutes (range 32–133 min-
utes).[35]
After oral administration, the THC plasma con-
centration shows a flat course with peaks of 4.4–11
μg/L after THC 20mg,[39] 2.7–6.3 μg/L after THC
15mg[46] and 0.58–12.48 μg/L after THC 2.5mg
(figure 6).[44] Much higher amounts of 11-OH-
THC are formed than with inhalational or intrave-
nous administration.[25,31,46] In a study by Wall et
al., the ratio of THC and 11-OH-THC plasma con-
centrations in men and women was about 2 : 1 to
1 : 1.[31] In several clinical studies,[44,46] 11-OH-
THC concentrations even exceeded THC concen-
trations. In a study with dronabinol 2.5 mg/day,
mean maximal THC concentrations were 2.01
μg/L compared with 4.61 μg/L for 11-OH-THC.[44]
The course of THC plasma concentrations shows
a high interindividual variation (figure 8).
3.5 Elimination
3.5.1 Elimination from Plasma
About 6 hours after intravenous administration
of THC a pseudoequilibrium is reached between
plasma and tissues.[64] The concentration in plasma
usually has dropped below 2 μg/L at this time and
than decreases more slowly with increasing time
from use.[35,40]
After smoking a low dose cannabis cigarette
(about 16mg of THC), the detection limit of 0.5
μg/L of THC in plasma was reached after 7.2 hours
O
11CH3
OH
CH2OH
COOH
CO-O-Glucuronide
Fatty acid conjugate
HO
8
Fig. 7. Main metabolic pathways of Δ9-tetrahydrocannabinol.
336
Grotenhermen
© Adis International Limited. All rights reserved.
Clin Pharmacokinet 2003; 42 (4)

(range 3–12 hours), and following a high dose cig-
arette (about 34mg of THC) a plasma concentra-
tion of 0.5 μg/L of THC was reached within 12.5
hours (range 6–27 hours).[35] THC-COOH was de-
tectable for a considerably longer time: for 3.5
days (range 2–7 days) after the low dose and for
6.3 days (range 3–7 days) after smoking the high
dose.[35]
The major reason for the slow elimination of
THC from the plasma is the slow rediffusion of
THC from body fat and other tissues into the
blood.[53]
The true elimination half-life of THC from the
plasma is difficult to calculate, as the equilibrium
ratio plasma/fatty tissue is reached only slowly,
resulting in very low plasma concentrations that
are difficult to analyse. In a study by Wall et al.,
the half-life of the terminal phase (t1⁄2β) ranged
from 25–36 hours for THC, from 12–36 hours for
11-OH-THC and from 25–55 hours for THC-
COOH after oral or intravenous administration in
men and women.[31] The plasma concentration was
followed for 72 hours in this study, not long
enough to determine the half-life accurately. Sim-
ilar elimination half-lives for THC in the range of
20–30 hours determined over similar periods have
been reported by others.[32,42,57]
Table IV. Pharmacokinetic data for Δ9-tetrahydrocannabinol
Subjects
Dose (mg)
AUC (μg • min/L)
Cmax (μg/L)
t1⁄2β (h)
Vd (L)
CL (ml/min)
References
Intravenous
4 nonusers
0.5
57 ± 4
658 ± 174
57
5 regular users
0.5
27 ± 1
597 ± 76
57
6 males (drug free)
2
19.6 ± 4.1
626 ± 296
605 ± 149
32
6 males (long-term)
2
18.7 ± 4.2
742 ± 331
977 ± 304
32
6 males
4
70 ± 30
36
734 ± 444
248 ± 62
31
6 females
2.2
85 ± 26
29
523 ± 217
197 ± 50
31
11 males
5
4330 ± 620
161-316
37, 39
9 heavy users
5
4300 ± 1670
288 ± 119
38
9 light users
5
6040 ± 2.21
302 ± 95
38
5 heavy users
5
5180 ± 830
>20
980 ±150
42
4 light users
5
5460 ± 1180
>20
950 ± 200
42
4 heavy users
5
9908 ± 3785
438 ± 36
1.9 ± 0.3
75 ± 16
777 ± 690
33
4 light users
5
7094 ± 2248
386 ± 29
1.6 ± 0.5
74 ± 35
771 ± 287
33
Oral
6 males
20
14.5 ± 9.7
25
31
6 females
15
9.4 ± 4.5
25
31
11 males
20
1020 ± 320
4.4–11
37, 39
3 males
3 × 15
4–6
46
3 males, 3 females
15
3–5
46
20 AIDS patients
2 × 2.5
2.01
(0.58–12.48)
44
7 men, 10 women
10
610 ± 310
4.7 ± 3.0
41
Inhalational
11 males
19
1960 ± 650
33–118
37, 39
9 heavy users
19
2160 ± 1030
98 ± 44
38
9 light users
19
1420 ± 740
67 ± 38
38
5 heavy users
10
2450 ± 530
42
4 light users
10
1420 ± 340
42
6 males
15.8
84 (50–129)
35
6 males
33.8
162 (76–267)
35
AUC = area under the concentration-time curve; CL = systemic clearance; Cmax = maximum plasma concentration; t1⁄2β = plasma elimination
half-life; Vd = volume of distribution.
Cannabinoids
337
© Adis International Limited. All rights reserved.
Clin Pharmacokinet 2003; 42 (4)

Longer half-lives of THC plasma elimination
have been determined after higher doses and
longer periods of measurement in animals[69] and
humans,[93] up to 12.6 days with 4 weeks of obser-
vation.[93] However, it is unclear whether THC
could always be reliably distinguished from its me-
tabolites, thus overestimating the length of the
half-life.[33] Kelly and Jones measured a t1⁄2β for
THC of only 117 minutes for frequent and 93 min-
utes for infrequent users.[33]
The elimination half-life for THC metabolites
from plasma is longer than the elimination half-life
of the parent molecule. In a study by Hunt and
Jones,[32] the medium t1⁄2β  of THC for frequent us-
ers was about 19 hours and of the overall metabo-
lites 53 hours. In the study by Kelly and Jones , the
plasma elimination half-life for THC-COOH was
5.2 ± 0.8 days for frequent and 6.2 ± 6.7 days for
infrequent cannabis users.[33]
3.5.2 Excretion with Urine and Faeces
THC is excreted within days and weeks, mainly
as acid metabolites, about 20–35% in urine and
65–80% in faeces, less than 5% of an oral dose as
unchanged drug in the faeces.[31,32] After 3 days,
overall excretion rates were about 65% following
oral and about 45% with intravenous administra-
tion (see table V).[31]
A single dose of THC may result in detectable
metabolites in urine for up to 12 days,[45] usually
for 3–5 days.[94] The average time to the first neg-
ative result in urine screening for THC metabolites
(enzyme immunoassay with a cut-off calibration
of 20 μg/L) was 8.5 days (range 3–18 days) for
infrequent users and 19.1 days (range 3–46 days)
for regular users.[95] Since urine excretion of me-
tabolites does not decrease monotonously, urine
screenings may fluctuate between positive and
negative results for several days. The average time
until the last positive result was 12.9 days (3–29
days) for light users and 31.5 days (4–77 days) for
heavy users.[95]
A urinary excretion half-life of THC-COOH of
about 30 hours was observed with a 7-day moni-
toring period and of 44–60 hours with a 14-day
period.[96] Other groups calculated similar average
urinary excretion half lives of about 2 days with a
12-day monitoring period[33] and of about 3 days
(range 0.9–9.8 days) when THC-COOH was mea-
sured for 25 days.[97]
Mainly acids are excreted with the urine,[98,99]
the main metabolite being the acid glucuronide of
THC-COOH.[100] Free THC-COOH is not excreted
in significant concentrations.[33,45,101] Several au-
thors reported that the concentrations of THC and
11-OH-THC in urine were insignificant,[18,102] but
a recent study found significant concentrations of
0
1
2
3
4
5
Time after oral ingestion (h)
Concentration (μg/L)
Patient 3
Patient 5
Patient 6
12
10
8
6
4
2
0
Fig. 8. Plasma concentrations of Δ9-tetrahydrocannabinol
(THC) of three of the six cancer patients of figure 6 after inges-
tion of one oral dose of THC 15mg (estimated from graphs of
figure 2 of Frytak et al.,[46] with permission).
Table V.  Mean cumulative cannabinoid excretion[31]
Subjects/route
Urine (%)
Faeces (%)
Total (%) at 72h
% of total in urine at 72h
24h
72h
24h
72h
Women/intravenous
11 ± 2
16 ± 3
9 ± 11
26 ± 19
42
38.1
Men/intravenous
10 ± 5
15 ± 4
14 ± 11
35 ± 11
50
30.0
Women/oral
12.5 ± 3.0
15.9 ± 3.6
9 ± 11
48 ± 6
63.9
24.9
Men/oral
10.3 ± 2.1
13.4 ± 2.0
24 ± 42
53 ± 18
66.4
20.2
338
Grotenhermen
© Adis International Limited. All rights reserved.
Clin Pharmacokinet 2003; 42 (4)

these neutral cannabinoids by using an enzymatic
hydrolysis step in the extraction protocol, with
THC concentrations peaking at 21.5 μg/L (range
3.2–53.3 μg/L) 2 hours after smoking THC 27mg
in a cannabis cigarette, 11-OH-THC peaking at
77.3 ± 29.7 μg/L after 3 hours and THC-COOH
peaking at 179.4 ± 146.9 μg/L after 4 hours (figure
9).[103]
Renal clearance has been reported to decrease
from a maximum of 1.2 L/h (20 ml/min) at approx-
imately 100 minutes to 0.06 L/h (1 ml/min) after 4
days of THC administration.[32] The high lipophil-
icity of THC, resulting in high tubular reabsorp-
tion, explains the low renal excretion of the un-
changed drug.[18]
Excretion is delayed by an extensive enterohep-
atic recirculation of metabolites.[31,102] Due to this
marked enterohepatic recirculation and the high
protein binding of cannabinoids, they are predom-
inantly excreted with the faeces. In contrast to
urine excretion, the acid and neutral THC metabo-
lites in the faeces are only present in the noncon-
jugated form.[31,104]
3.6 Time–Effect Relationship
3.6.1 Correlation of Time and Effects
Peak ‘highs’ after intravenous and inhalational
administration were noted after 20–30 minutes,
and decreased to low levels after 3 hours and to
baseline after 4 hours (figure 10).[36-38] Maximum
increase of heart rate was noted earlier, within a
few (1–5) minutes decreasing to baseline after 3
hours.[38] Conjunctival reddening was also noted
within a few minutes and subsided in some partic-
ipants by 3 hours after smoking.[42] Duration of
maximal effects is dose dependent, and was found
to be 45 minutes after THC 9mg[105] and more than
60 minutes with higher doses.[106]
Following inhalation, THC plasma concentra-
tions have already dropped significantly before
maximal psychotropic effects are achieved.[36,39] It
has been proposed that the first hour represents the
distribution phase[60] and that after 1 hour the cen-
tral compartment has reached equilibrium with the
effect compartment.[36] Hence, about 1–4 hours af-
20
40
60
80
100
120
140
160
180
0
1
2
3
4
5
6
Time after smoking (h)
Concentration (μg/L)
0
THC
11-OH-THC
THC-COOH
Fig. 9. Mean urine concentrations of unchanged Δ9-tetrahydro-
cannabinol (THC) and its major metabolites 11-hydroxy-THC
(11-OH-THC) and 11-nor-9-carboxy-THC (THC-COOH) after
smoking a cannabis cigarette containing about 27mg of THC
by eight subjects with self-reported history of light marijuana use
(one to three cigarettes per week or less). One subject later
admitted regular use and presented with high baseline concen-
trations of 11-OH-THC and THC-COOH.[103]
0
1
2
3
4
5
6
7
8
9
10
0
1
2
3
4
5
6
Time after administration (h)
Subjective high
Intravenous (5mg)
Smoked (19mg)
Oral (20mg)
Fig. 10. Time course of subjective effects following three modes
of administration of Δ9-tetrahydrocannabinol. A rating of the de-
gree of ‘high’ was made by subjects on a 0–10 scale.[37,39]
Cannabinoids
339
© Adis International Limited. All rights reserved.
Clin Pharmacokinet 2003; 42 (4)

ter smoking there is a good correlation between
plasma concentration and effects.[36,107,108]
After oral use (THC 20mg in a cookie), redden-
ing of the conjunctivae occurred within 30–60
minutes and was maximal from 60–180 minutes,
gradually lessening thereafter.[39] As with inhala-
tion, the pulse rate often returned to baseline or
below even while the participants felt ‘high’.[39]
Psychotropic effects after oral use set in after 30–
90 minutes,[31,37] were maximal between 2 and 4
hours, and declined to low levels after 6 hours.[37]
Maximal psychotropic effects were usually de-
layed for 1–3 hours, when plasma concentrations
had already started to fall.[37]
3.6.2 Pharmacokinetic-Pharmacodynamic
Modelling
With both inhalational and oral use, the associ-
ation between THC concentrations in the plasma
and subsequent psychotropic effects describes a
hysteresis over time (figure 11). The intensity of
THC effects depends on the concentration in the
effect compartment. Although THC quickly
crosses the blood-brain barrier,[109] plasma con-
centrations are already falling while brain concen-
trations are still rising.[109-111] In monkeys, an in-
travenous dose of radiolabelled THC resulted in
peak radioactivity levels in the brain after 15–60
minutes, in accordance with the time of maximal
effect after intravenous and inhalational adminis-
tration in humans.[110] Chiang and Barnett[36] have
proposed a kinetic and dynamic model based on an
open two-compartment model (figure 12).
According to the Hill equation, there is a rela-
tionship between the intensity of the psychotropic
effects (E) and the amount of THC in the effect
compartment (Ae) [equation 1]:
The steady-state plasma concentration at 50%
of the maximum psychotropic effect (Css,50) was
ascertained to be 25–29 μg/L by using cannabis
cigarettes of three different potencies.[36] The elim-
ination rate constant from the effect compartment
(ke0) was 0.03–0.04 min–1, and the sigmoid pa-
rameter γ (the degree of sigmoidicity of the ef-
fect/amount relationship) was 1.5–2.0. The trans-
fer rate constant k21 from the tissue compartment
was much smaller (0.0078–0.012 min–1) than the
elimination rate constant. Thus, the time course of
effects must precede the time course of the THC
0
1
2
3
4
5
Plasma concentration (μg/L)
Subjective high
6
5
4
3
2
1
0
Fig. 11. Phase plot of subjective ‘high’ versus plasma Δ9-tetra-
hydrocannabinol (THC) concentration from 0–360 minutes after
oral ingestion of THC 15mg in a chocolate cookie.[37] Every solid
point in the figure marks 30 minutes of time. The maximum THC
plasma concentration (5.7 μg/L) was reached after 60 minutes,
whereas the maximum subjective ‘high’ (on a 0–10 scale; see
figure 10) was noted 2–4 hours after intake of the cannabinoid.
Dose
k1e
Ae, Ve
effect
V1
central
V2
tissue
ke0
k12
k21
k10
Ka
Fig. 12. Kinetic and dynamic model for Δ9-tetrahydrocannabinol
(THC).[36] Ka , k12, k21 and k10 describe THC kinetics in the em-
pirical two-compartment model. The rate constants k1e and ke0
characterise the effect compartment. Ae is the amount of THC
in the effect compartment. Ve, V1 and V2 are the volumes of the
respective compartments.
E
k
A
k
V
k
A
k
V
C
e
e
e
e
e
e
ss
 

(
/
)
(
/
)
,
0
1
1
0
1
1
50
•
•


•
•
340
Grotenhermen
© Adis International Limited. All rights reserved.
Clin Pharmacokinet 2003; 42 (4)

amount in the tissue compartment.[36] The rate con-
stant k10 probably consists of a mixture of con-
stants for metabolism and distribution between the
central and deep tissue compartments.[36]
3.6.3 Predicting Time of Use
Several methods and models have been pro-
posed for predicting time of administration. They
are based on THC plasma concentrations[112,113] or
the ratio of THC and its metabolites THC-COOH
and 11-OH-THC in the plasma.[45,114-116] The
higher the THC-COOH/THC ratio the longer time
has passed since consumption.
In urine, THC concentrations above 2 μg/L
were proposed as a marker for cannabis use within
5 hours after smoking (figure 9).[103] Others sug-
gested that 8β,11-dihydroxy-THC showed prom-
ise as a urine marker for recent use,[113] whereas
Manno et al. detected 8β,11-dihydroxy-THC only
in the urine of a regular user and not in the urine
of the light users in his study.[103]
3.7 Pharmacokinetics of
Other Cannabinoids
The pharmacokinetics of other cannabinoids
resemble the kinetics of THC.[117] Pharmacoki-
netics will be reviewed briefly for the phyto-
cannabinoid cannabidiol, for nabilone, a synthetic
ketocannabinoid that is available on prescription
in several countries, and for dexanabinol, a non-
psychotropic analogue of Δ8-THC under clinical
investigation.
3.7.1 Cannabidiol
Average systemic bioavailability of inhaled
CBD in a group of cannabis users was 31% (range
11–45%).[118] The plasma pattern was similar to
that of THC. After oral administration of CBD
40mg, the plasma course over 6 hours was in the
same range as the course after THC 20mg.[119]
Daily oral doses of CBD 10 mg/kg per day for 6
weeks in patients with Huntington’s disease re-
sulted in mean weekly plasma concentrations of
5.9–11.2 μg/L.[120] In rats receiving intravenous
THC and CBD (each 1 mg/kg bodyweight), brain
concentrations of unchanged CBD were higher
than that of THC 5 minutes after administration.[83]
The volume of distribution was about 30 L/kg,
greater than for THC,[118] and the plasma clearance
was similar to that of THC, ranging from 58 to 94
L/h (960–1560 ml/min).[118] An average t1⁄2β of 24
hours (range 18–33 hours) during an observation
period of 72 hours was determined after intrave-
nous injection of 20mg.[118]
The metabolic pattern is similar to that of
THC.[121,122] Several cyclised cannabinoids were
identified, among them Δ9-THC, Δ8-THC and can-
nabinol.[121] The excretion rate of metabolites in
urine (16% in 72 hours) is similar to that of
THC,[122] whereas unlike THC a high percentage
of unchanged CBD is excreted in the faeces.[122]
3.7.2 Nabilone
The absorption of oral nabilone (as a poly-
vinylpyrrolidone coprecipitate) is nearly com-
plete,[123] with plasma concentrations peaking at
1–4 hours. Nabilone was reported to disappear
from plasma relatively fast, with a half-life of
about 2 hours,[123,124] and total radioactivity disap-
peared slowly with a half-life of 30 hours.[123] Cir-
culating metabolites in plasma include isomeric
carbinols with long half lives formed by reduction
of the ketone at C-9.[124-126]
3.7.3 Dexanabinol
The pharmacokinetics of the synthetic non-
psychotropic cannabinoid dexanabinol (HU-211)
were evaluated with doses of 48, 100 and 200mg
as short intravenous infusions in healthy volun-
teers. The plasma course was best fitted to a three-
compartment model with a t1⁄2β of approximately 9
hours.[59] The plasma clearance of the drug (about
102 L/h [1700 ml/min]) and the volume of distri-
bution (about 15 L/kg) were somewhat higher than
seen with THC.
3.7.4 Metabolic Interaction of Cannabinoids
Metabolic interaction between cannabinoids
has been observed, but only cannabidiol seems to
have a significant effect on THC by inhibiting he-
patic microsomal THC metabolism through inac-
tivation of the CYP oxidative system.[127-130]
Cannabinoids
341
© Adis International Limited. All rights reserved.
Clin Pharmacokinet 2003; 42 (4)

Treatment of mice with high doses of CBD (120
mg/kg) resulted in changes of metabolism of THC
(12 mg/kg) and modest elevation of THC blood
concentrations.[131] Brain concentrations of THC
increased by nearly 3-fold.[131] However, there was
no or minimal effect of CBD on THC plasma con-
centrations in humans.[119,132] Repeated adminis-
tration of THC and THC metabolites,[133,134] other
cannabinoid receptor agonists[135] and even CBD[133]
increased the activity of CYP by enzyme induc-
tion, thus decreasing the inactivating effect caused
by CBD.
In humans, pretreatment with oral CBD 40mg
resulted in a delayed, longer and only slightly re-
inforced action of oral THC 20mg.[136] However,
simultaneous administration of CBD and THC re-
sulted in a significant block of several THC effects,
among them anxiety and other subjective alter-
ations caused by THC[137] and tachycardia,[138]
presumably due to antagonistic interaction of CBD
at the CB1 receptor.[139]
4. Pharmacodynamics
4.1 Mechanism of Action
The majority of phytocannabinoid effects are
mediated through agonistic or antagonistic actions
at specific receptors sites. Cannabinoid receptors
and their endogenous ligands together constitute
the ‘endogenous cannabinoid system’ or the ‘en-
docannabinoid system’ that is teleologically mil-
lions of years old.[140]
Some non-receptor-mediated effects of phyto-
cannabinoids and synthetic derivatives have also
been described e.g. effects on the immune sys-
tem,[141] neuroprotective effects in ischaemia and
hypoxia,[142] and some effects on circulation.[143]
The antiemetic effects of THC are in part non-
receptor-mediated, the rationale for the clinical use
of THC as an antiemetic in children receiving can-
cer chemotherapy.[144] Due to the lower CB1 recep-
tor density in the brain of children compared with
adults, they tolerated relatively high doses of Δ8-
THC in a clinical study without significant adverse
effects.[144] It is possible that some of these effects
are mediated by cannabinoid receptor subtypes
that have not yet been identified.
4.1.1 Cannabinoid Receptors
To date, two cannabinoid receptors have been
identified, CB1 receptors (cloned in 1990) and CB2
receptors (cloned in 1993),[145] both coupled
through inhibiting G proteins (Gi proteins), nega-
tively to adenylate cyclase and positively to mito-
gen-activated protein kinase. Activation of Gi pro-
teins causes inhibition of adenylate cyclase, thus
inhibiting the conversion of AMP to cyclic AMP.
CB1 receptors are also coupled to ion channels
through Gi/o, negatively to N-type and P/Q-type
calcium channels and positively to A-type and in-
wardly rectifying potassium channels.[146] They
may also mobilise arachidonic acid and close sero-
tonin (5-HT3) receptor ion channels,[146] and some
CB1 receptors are negatively coupled to M-type
potassium channels.[147] Under certain conditions,
they may also activate adenylate cyclase through
stimulating G proteins (Gs proteins).[148]
CB1 receptors are found mainly on neurons in
the brain, spinal cord and peripheral nervous sys-
tem, but are also present in certain peripheral or-
gans and tissues, among them endocrine glands,
leucocytes, spleen, heart and parts of the reproduc-
tive, urinary and gastrointestinal tracts.[145]
CB2 receptors occur principally in immune
cells, among them leucocytes, spleen and ton-
sils,[146] and there is markedly more mRNA for
CB2 than for CB1 in the immune system. Levels of
CB1 and CB2 mRNA in human leucocytes have
been shown to vary with cell type (B cells > natural
killer cells > monocytes > polymorphonuclear neu-
trophils, CD4+ and CD8+ cells).[149]
There is some evidence for the existence of one
or more additional cannabinoid receptor sub-
types.[150-152]
Activation of the CB1 receptor produces mari-
juana-like effects on psyche and circulation,
whereas activation of the CB2 receptor does not.
Hence, selective CB2 receptor agonists have be-
come an increasingly investigated target for
therapeutic uses of cannabinoids, among them an-
342
Grotenhermen
© Adis International Limited. All rights reserved.
Clin Pharmacokinet 2003; 42 (4)

algesic, anti-inflammatory and antineoplastic ac-
tions.[153,154]
4.1.2 Endocannabinoids
The identification of cannabinoid receptors was
followed by the detection of endogenous ligands
for these receptors, endogenous cannabinoids or
endocannabinoids, a family of endogenous lipids
(figure 13).[6,155,156] The most important of these
endocannabinoids are arachidonylethanolamide
(anandamide) and 2-arachidonylglycerol, both of
which are thought to serve as neurotransmitters or
neuromodulators.[146,157] Endocannabinoids are
released from cells in a stimulus-dependent man-
ner by cleavage of membrane lipid precursors.[155]
After release, they are rapidly deactivated by up-
take into cells via a carrier-mediated mechanism
and enzymatic hydrolysis by fatty acid amide
hydrolase (FAAH).[155,158] In mice, lack of FAAH
resulted in supersensitivity to anandamide and en-
hanced endogenous cannabinoid signalling.[159]
4.1.3 Affinity for the Cannabinoid Receptor
Cannabinoids show different affinity to CB1
and CB2 receptors. Synthetic cannabinoids have
been developed that act as highly selective ago-
nists or antagonists at one of these receptor
types.[146,160,161] Δ9-THC has approximately equal
affinity for the CB1 and CB2 receptor, whereas an-
andamide has marginal selectivity for CB1 recep-
tors.[161] However, the efficacy of THC and an-
andamide is less at CB2 than at CB1 receptors. As
a partial (low-efficacy) agonist, THC can behave
either as an agonist or antagonist at CB2 recep-
tors.[146]
4.1.4 Tonic Activity of the
Endocannabinoid System
The endogenous cannabinoid system has been
demonstrated to be tonically active in several con-
ditions. Endocannabinoid levels have been dem-
onstrated to be increased in a pain circuit of the
brain (periaqueductal gray) following painful
stimuli.[162] Tonic control of spasticity by the endo-
cannabinoid system has been observed in chronic
relapsing experimental autoimmune encephalo-
myelitis (CREAE) in mice, an animal model of
multiple sclerosis.[163] An increase of cannabinoid
receptors following nerve damage was demon-
strated in a rat model of chronic neuropathic
pain[164] and in a mouse model of intestinal inflam-
mation.[165] This may increase the potency of can-
nabinoid agonists used for the treatment of these
conditions. Tonic activity has also been demon-
strated with regard to appetite control[166] and with
regard to vomiting in emetic circuits of the
brain.[167] Elevated endocannabinoid levels have
been detected in cerebrospinal fluid of schizophre-
nic patients.[168] In other models, tonic or enhanced
activity could not be demonstrated, e.g. in a rat
model of inflammatory hyperalgesia.[169]
4.2 Pharmacological Effects of
Δ9-Tetrahydrocannabinol
The pharmacological activity of Δ9-THC is
stereoselective, with the natural (–)-trans isomer
(dronabinol) being 6–100 times more potent than
the (+)-trans isomer depending on the assay.[2]
H
N
OH
O
9
8
6
5
3
10
11
12
14
15
17
19
β
α
Arachidonylethanolamide (anandamide)
O
OH
O
CH2OH
2-Arachidonylglycerol
H
N
OH
O
Palmitylethanolamide
Fig. 13. Major endocannabinoids.
Cannabinoids
343
© Adis International Limited. All rights reserved.
Clin Pharmacokinet 2003; 42 (4)

The activation of the cannabinoid system
through THC and other phytocannabinoids, syn-
thetic and endogenous cannabinoids causes
numerous actions that have been extensively re-
viewed (see table VI).[2,3,170-175] Additional non-
receptor-mediated effects have come into focus as
well.[142] Some effects of cannabinoid receptor ag-
onists show a biphasic behaviour in dependency
on dose, e.g. low doses of anandamide stimulated
phagocytosis and stimulated behavioural activities
in mice, whereas high doses decreased activities
and caused inhibitory effects on immune func-
tions.[176]
4.2.1 Toxicity
The median lethal dose (LD50) of oral THC in
rats was 800–1900 mg/kg depending on sex and
strain.[177] There were no cases of death due to tox-
icity following the maximum oral THC dose in
dogs (up to 3000 mg/kg THC) and monkeys (up to
9000 mg/kg THC).[177] Acute fatal cases in humans
have not been substantiated. However, myocardial
infarction may be triggered by THC due to effects
on circulation.[178,179]
Adverse effects of medical cannabis use are
within the range of effects tolerated for other med-
ications.[173,174] It is controversial whether heavy
regular consumption may impair cognition,[180,181]
but this impairment seems to be minimal if it ex-
ists.[182,183] Long-term medical use of cannabis has
been reported to be well tolerated without signifi-
cant physical or cognitive impairment.[184] There
is conflicting evidence that infants exposed to THC
in utero experience developmental and cognitive
impairment.[185] Cannabis can induce a schizo-
phrenic psychosis in vulnerable persons, presum-
ably without increasing the incidence of the dis-
ease.[172,186]
The harmful effects of combustion products
produced by smoking cannabis have to be distin-
guished from the effects of cannabis or single can-
nabinoids.[174]
Table VI.  Physiological effects of Δ9-tetrahydrocannabinol. These dose-dependent effects have been observed in clinical studies, in vivo or
in vitro
Body system
Effects
Psyche and perception
Fatigue, euphoria, enhanced well-being, dysphoria, anxiety, reduction of anxiety,
depersonalisation, increased sensory perception, heightened sexual experience,
hallucinations, alteration of time perception, aggravation of psychotic states, sleep
Cognition and psychomotor performance
Fragmented thinking, enhanced creativity, disturbed memory, unsteady gait,
ataxia, slurred speech, weakness, deterioration or amelioration of motor
coordination
Nervous system
Analgesia, muscle relaxation, appetite stimulation, vomiting, antiemetic effects,
neuroprotection in ischaemia and hypoxia
Body temperature
Decrease of body temperature
Cardiovascular system
Tachycardia, enhanced heart activity, increased output, increase in oxygen
demand, vasodilation, orthostatic hypotension, hypertension (in horizontal
position), inhibition of platelet aggregation
Eye
Reddened conjunctivae, reduced tear flow, decrease of intraocular pressure
Respiratory system
Bronchodilation
Gastrointestinal tract
Hyposalivation and dry mouth, reduced bowel movements and delayed gastric
emptying
Hormonal system
Influence on luteinising hormone, follicle-stimulating hormone, testosterone,
prolactin, somatotropin, thyroid-stimulating hormone, glucose metabolism,
reduced sperm count and sperm motility, disturbed menstrual cycle and
suppressed ovulation
Immune system
Impairment of cell-mediated and humoral immunity, immune stimulation,
anti-inflammatory and antiallergic effects
Fetal development
Malformations, growth retardation, impairment of fetal and postnatal cerebral
development, impairment of cognitive functions
Genetic material and cancer
Antineoplastic activity, inhibition of synthesis of DNA, RNA and proteins
344
Grotenhermen
© Adis International Limited. All rights reserved.
Clin Pharmacokinet 2003; 42 (4)

4.2.2 Psyche, Cognition and Behaviour
In many species the behavioural actions of low
doses of THC are characterised by a unique mix-
ture of depressant and stimulant effects in the
CNS.[2]
In humans, THC intoxication is usually de-
scribed as a pleasant and relaxing experience. Use
in a social context may result in laughter and talk-
ativeness. Occasionally there are unpleasant feel-
ings such as anxiety that may escalate to panic. A
sense of enhanced well-being may alternate with
dysphoric phases. THC improves taste responsive-
ness and enhance the sensory appeal of foods.[187]
It may induce sleep.[188,189] Whole cannabis prep-
arations and THC produce similar subjective ef-
fects if administered via the same routes (oral, in-
halation).[190]
Acute THC intoxication impairs learning and
memory, [191-193] and adversely affects psychomo-
tor and cognitive performance,[186] reducing the
ability to drive a car and to operate machinery.
Reduced reaction time also affects the response of
the pupil of the eye. A brief light flash causes a
decreased amplitude of constriction and a reduced
velocity of constriction and dilation.[194]
The most conspicuous psychological effects of
THC in humans have been divided into four
groups: affective (euphoria and easy laughter),
sensory (increased perception of external stimuli
and of the person’s own body), somatic (feeling of
the body floating or sinking in the bed) and cogni-
tive (distortion of time perception, memory lapses,
difficulty in concentration).[195]
4.2.3 Central Nervous System
and Neurochemistry
Most effects of THC (e.g. analgesia, appetite
enhancement, muscle relaxation and hormonal ac-
tions) are mediated by central cannabinoid recep-
tors, their distribution reflecting many of the me-
dicinal benefits and adverse effects.[146,191,196]
Cannabinoids interact with a multitude of neu-
rotransmitters and neuromodulators,[2,197] among
them acetylcholine, dopamine, γ-aminobutyric
acid (GABA), histamine, serotonin, glutamate,
norepinephrine, prostaglandins and opioid pep-
tides. A number of pharmacological effects can be
explained (at least in part) on the basis of such
interactions. For example, tachycardia and hypo-
salivation with dry mouth[187,198] are mediated by
effects of THC on release and turnover of acetyl-
choline.[198] In a rat model, cannabinoid agonists
inhibited activation of serotonin 5-HT3 receptors,
explaining the antiemetic properties of cann-
abinoids by interactions with serotonin.[199] Ther-
apeutic effects on movement and spastic disorders
could be ascribed in part to interactions with
GABAergic, glutaminergic and dopaminergic
transmitter systems.[200,201]
4.2.4 Circulatory System
THC can induce tachycardia[195] and increase
cardiac output with increased cardiac work and ox-
ygen demand.[202] It can also produce peripheral
vasodilation, orthostatic hypotension[3,203] and
reduced platelet aggregation.[204] There was no
change of mean global cerebral blood flow after
smoking cannabis, but increases and decreases in
several regions.[205] The tachycardic effect of THC
is presumably based on vagal inhibition and can be
attenuated by β-blockers.[195] Due to the develop-
ment of tolerance, long-term use can lead to brady-
cardia.[203] The endogenous cannabinoid system
seems to play a major role in the control of blood
pressure. Endocannabinoids are produced by the
vascular endothelium, circulating macrophages
and platelets.[206] Vascular resistance in the coro-
naries and the brain is lowered primarily by direct
activation of vascular cannabinoid CB1 recep-
tors.[207]
4.3 Effects on Some Other Organ Systems
4.3.1 Antibacterial and Antiviral Actions
Antibacterial actions have been demonstrated
for CBD, CBG and THC.[208] Incubation with THC
reduced the infectious potency of herpes simplex
viruses.[209]
4.3.2 Eye
The evidence of cannabinoid receptors at differ-
ent sites (anterior eye, retina, corneal epithelium)
suggests that cannabinoids influence different
Cannabinoids
345
© Adis International Limited. All rights reserved.
Clin Pharmacokinet 2003; 42 (4)

physiological functions in the human eye.[210] Va-
sodilation in the eye is observed as conjunctival
reddening after THC exposure.[2] THC and some
other cannabinoids decrease intraocular pres-
sure.[210,211]
4.3.3 Hormonal System and Fertility
THC interacts with the hypothalamic-pituitary-
adrenal axis, influencing numerous hormonal pro-
cesses.[212] Minor changes in human hormone lev-
els due to acute cannabis or THC ingestion usually
remain in the normal range.[3] Tolerance develops
to these effects, however, and even regular canna-
bis users demonstrate normal hormone levels.
4.3.4 Genetics and Cell Metabolism
THC can inhibit DNA, RNA, and protein syn-
thesis, and can influence the cell cycle. However,
very high doses are required to produce this effect
in vitro.[213] Cannabinoid agonists inhibited human
breast cancer cell proliferation in vitro,[214,215] and,
directly applied at the tumour site, showed anti-
neoplastic activity against malignant gliomas in
rats.[216]
4.3.5 Immune System
Animal and cell experiments have demon-
strated that THC exerts complex effects on cellular
and humoral immunity.[217,218] It is not clear
whether and to what extent these effects are of clin-
ical relevance in humans with respect to beneficial
(inflammation,[219,220] allergies, autoimmune pro-
cesses[218]) and undesirable (decreased resistance
towards pathogens and carcinogens) effects.[217]
4.3.6 Sperm
After several weeks of daily smoking eight to
ten cannabis cigarettes, a slight decrease in sperm
count was observed in humans, without impair-
ment of their function.[221] In animal studies, high
doses of cannabinoids inhibited the acrosome re-
action.[222]
4.3.7 Digestive Tract
Anandamide induces overeating in rats through
a CB1 receptor mediated mechanism.[223] Can-
nabinoid-induced eating is ascribed to an increase
of the incentive value of food.[224] Cannabinoid ag-
onists inhibit gastrointestinal motility and gastric
emptying in rats.[225] In a study with humans, THC
caused a significant delay in gastric emptying.[226]
In addition, CB1 agonists inhibited pentagastrin-
induced gastric acid secretion in the rat,[227] medi-
ated by suppression of vagal drive to the stomach
through activation of CB1 receptors.[228]
4.4 Pharmacological Activity of
Δ9-Tetrahydrocannabinol Metabolites
4.4.1 11-Hydroxy-Δ9-Tetrahydrocannabinol
11-OH-THC is the most important psychotropic
metabolite of Δ9-THC, with a similar spectrum of
actions and similar kinetic profiles as the parent
molecule.[122,229,230] After intravenous administra-
tion in humans, 11-OH-THC was equipotent to
THC in causing psychic effects and reduction in
intraocular pressure.[230] In some pharmacological
animal tests, 11-OH-THC was three to seven times
more potent than THC.[231]
4.4.2 11-Nor-9-Carboxy-Δ9-Tetrahydrocannabinol
THC-COOH is the most important non-
psychotropic metabolite of Δ9-THC. It possesses
anti-inflammatory and analgesic properties by
mechanisms similar to those of nonsteroidal anti-
inflammatory drugs.[232-234] THC-COOH antagon-
ises some effects (for example the cataleptic effect
in mice) of the parent drug through an unknown
mechanism.[235]
4.5 Pharmacological Effects
of Other Cannabinoids
4.5.1 Phytocannabinoids
Cannabidiol (CBD) is a nonpsychotropic can-
nabinoid, for which sedating,[236] antiepileptic,[237]
antidystonic,[238] antiemetic[239] and anti-inflam-
matory[240] effects have been observed. It reduced
intraocular pressure,[241] was neuroprotective[142]
and antagonised the psychotropic and several other
effects of THC.[137] Anxiolytic and antipsychotic
properties might prove useful in psychiatry.[137,236]
The nonpsychotropic cannabinoids CBG and
CBC show sedative effects. CBG has been ob-
served to decrease intraocular pressure,[211] showed
antitumour activity against human cancer cells[242]
and has antibiotic properties.
346
Grotenhermen
© Adis International Limited. All rights reserved.
Clin Pharmacokinet 2003; 42 (4)

4.5.2 Endocannabinoids
Anandamide (arachidonyl-ethanolamide), an
endocannabinoid, produces pharmacological ef-
fects similar to those of THC. However, there are
apparently some significant differences with THC.
Under certain circumstances, anandamide acts as
a partial agonist at the CB1 receptor,[243] and very
low doses of anandamide antagonised the actions
of THC. It is assumed that low doses of anandam-
ide activated stimulating Gs protein pathways and
not inhibiting Gi proteins, or caused an allosteric
modulation of the cannabinoid receptor.[243]
4.5.3 Classical Synthetic Cannabinoids
Among the classical synthetic cannabinoids
that retain the phytocannabinoid ring structures
and their oxygen atoms are nabilone, HU-210 and
dexanabinol. Nabilone is available on prescription
in several countries with a similar pharmacological
profile as THC (figure 14).[244] HU-210, an ana-
logue of Δ8-THC with a dimethylheptyl side chain,
is between 80 and 800 times more active than
THC,[245,246] while its enantiomer dexanabinol
(HU-211) is completely devoid of psychoactiv-
ity.[247] Dexanabinol is an N-methyl-D-aspartate
(NMDA) antagonist with neuroprotective proper-
ties in hypoxia and ischaemia.[248] It is under clin-
ical investigation for the treatment of brain injuries
and stroke.[248] CT-3 or ajulemic acid, a deriva-
tive of the Δ8-THC metabolite THC-COOH, is un-
der clinical investigation for inflammation and
pain.[65,249]
4.5.4 Nonclassical Synthetic Cannabinoids
Levonantradol, which was under clinical inves-
tigation for the treatment of pain[250] and the ad-
verse effects of chemotherapy[251] and radiother-
apy,[252] is a nonclassical cannabinoid with a more
radical change from the typical structure. Other
nonclassical cannabinoids are the aminoalkylindol
WIN-55,212-2, which has a 6.75-fold bias towards
the CB2 receptor[253] and the bicyclic cannabinoid
analogue CP-55,940, a widely-used agonist for the
testing of cannabinoid receptor affinity with a po-
tency 4–25 times greater than that of THC depend-
ing on assay.[254]
O
O
CH
Nabilone
O
OH
CH2OH
Dexanabinol (HU211)
COOH
O
OH
CT-3 (ajulemic acid)
Fig. 14. Classical synthetic cannabinoids.
Cannabinoids
347
© Adis International Limited. All rights reserved.
Clin Pharmacokinet 2003; 42 (4)

4.5.5 Anandamide Analogues
Several anandamide congeners have been
synthesised,[160] among them (R)-(+)-α-meth-
anandamide that possesses both a 4-fold higher
affinity for the CB1 receptor and a greater cata-
bolic resistance than anandamide. Fatty acid-
based compounds have been synthesised that
mimic the structure of anandamide, but act as
inhibitors of the catabolic amidase enzyme
FAAH.[158]
AM-404 is a synthetic fatty amide that acts as a
selective inhibitor of anandamide transport, thus
preventing cellular reuptake of anandamide[255]
and increasing circulating anandamide concentra-
tions.[155]
4.5.6 Therapeutic Potential of Antagonists
When administered by themselves, cannabinoid
receptor antagonists (e.g. SR141716A; figure 15)
may behave as inverse agonists in several bioassay
systems and produce effects that are opposite in
direction from those produced by cannabinoid
receptor agonists, e.g. hyperalgesia[256] and im-
provement of memory.[257] Possible therapeutic
potential was proposed for obesity,[258] schizo-
phrenia,[35] in conditions with lowered blood pres-
sure,[207] Parkinson’s disease,[259] Huntington’s
disease[260] and to improve memory in Alzheimer’s
disease.[35]
5. Tolerance and Dependency
5.1 Tolerance
Tolerance develops to most of the effects of
THC,[261] among them the cardiovascular, psycho-
logical and skin hypothermic effects,[262,263] anal-
gesia,[264] immunosuppression,[265] corticosteroid
release,[266] and disruption of the hypothalamo-
hypophyseal axis,[267] causing alterations in en-
docannabinoid formation and content in the
brain.[268] In a 30-day study volunteers received
daily oral doses of THC 210mg and developed
tolerance to cognitive and psychomotor impair-
ment and to the psychological ‘high’ by the end of
the study.[262] After a few days an increased heart
rate was replaced by a normal, or slowed, heart
rate. Tolerance also develops to orthostatic hypo-
tension.[203]
Tolerance can mainly be attributed to pharma-
codynamic changes, presumably based on receptor
downregulation and/or receptor desensitisa-
tion.[268,269] Rate and duration of tolerance varies
with different effects. Rats receiving THC over a
period of 5 days exhibited a decreased specific
binding ranging from 20–60% in different receptor
sites of the brain compared with controls.[261] How-
ever, in another study no significant alteration
in receptor binding was observed after chronic
administration of THC, resulting in 27-fold behav-
ioural tolerance.[270] Long-term administration of
N
N
CI
CI
N
N
O
CI
H
N
N
N
O
CI
H
a
b
Fig. 15. Cannabinoid receptor antagonists, SR 141716A (a) and SR 144528 (b).
348
Grotenhermen
© Adis International Limited. All rights reserved.
Clin Pharmacokinet 2003; 42 (4)

anandamide also resulted in behavioural tolerance
without receptor downregulation,[271] and it was
proposed that desensitisation of the CB1 receptor
might account for this observation.[271] Tolerance
has been observed to occur together with modified
biotransformation activities with regard to mito-
chondrial oxygen consumption, mono-oxygenase
activities and the content of liver microsomal
CYP.[135] However, only a small proportion of tol-
erance can be attributed to changes in metabo-
lism.[32]
5.2 Withdrawal and Dependency
After abrupt cessation of long-term administra-
tion of high doses of THC, withdrawal has been
observed in humans.[262,272] Subjects complained
of inner unrest, irritability and insomnia, and pre-
sented ‘hot flashes’, sweating, rhinorrhoea, loose
stools, hiccups and anorexia. Withdrawal symp-
toms in humans are usually mild and the risk for
physical and psychic dependency is low compared
with opioids, tobacco, alcohol and benzodia-
zepines.[273-275] A review of several indicators of
the abuse potential of oral dronabinol in a thera-
peutic context found little evidence of such a prob-
lem.[276]
6. Therapeutic Uses
Cannabis preparations have been employed
in the treatment of numerous diseases, with
marked differences in the available supporting
data.[171,173,174,277] Besides phytocannabinoids,
several synthetic cannabinoid derivatives that are
devoid of psychotropic effects are under clinical
investigation, and modulators of the endo-
cannabinoid system (such as reuptake inhibitors
and antagonists at the CB1 or CB2 receptor) will
presumably follow.
6.1 Hierarchy of Therapeutic Effects
Possible indications for cannabis preparations
have been extensively reviewed.[171,173,174,277-281]
To do justice to the scientific evidence with regard
to different indications, a hierarchy of therapeutic
effects can be devised, with established effects,
relatively well-confirmed effects, less confirmed
effects and a basic research stage. However the
history of research into the therapeutic benefits of
cannabis and cannabinoids has demonstrated that
the scientific evidence for a specific indication
does not necessarily reflect the actual therapeutic
potential for a given disease, but sometimes obsta-
cles to clinical research.
6.2 Established Effects
Dronabinol is approved for use in refractory nau-
sea and vomiting caused by antineoplastic drugs in
cancer[144,282-284] and for appetite loss in anorexia
and cachexia of HIV/AIDS patients.[285-287] These
effects can be regarded as established effects for
THC and cannabis. THC is also effective in cancer
cachexia[288] and nausea induced by syrup of ipe-
cac.[289] Nabilone is approved for nausea and vom-
iting associated with cancer chemotherapy.
6.3 Relatively Well-Confirmed Effects
Spasticity due to spinal cord injury[25,290,291]
and multiple sclerosis,[25,291-296] chronic painful
conditions, especially neurogenic pain,[290,291,297-301]
movement disorders (including Tourette’s syn-
drome, dystonia and levodopa-induced dyskine-
sia),[200,302-308] asthma[30,309,310] and glaucoma[28,311-314]
can be regarded as relatively well-confirmed ef-
fects with small placebo-controlled trials demon-
strating benefits. However, results were some-
times conflicting.
6.4 Less Confirmed Effects
There are several indications in which mainly
only case reports suggest benefits. These are al-
lergies,[315] inflammation,[174] epilepsy,[316] intrac-
table hiccups,[317] depression,[287] bipolar dis-
orders,[318] anxiety disorders,[174] dependency on
opioids and alcohol,[315,319] withdrawal symp-
toms[319] and disturbed behaviour in Alzheimer’s
disease.[320]
Cannabinoids
349
© Adis International Limited. All rights reserved.
Clin Pharmacokinet 2003; 42 (4)

6.5 Basic Research Stage
Basic research shows promising possible future
therapeutic indications, among them neuroprotec-
tion in hypoxia and ischaemia due to traumatic
head injury, nerve gas damage and stroke.[142,248]
Some immunological mechanisms of THC hint of
possible benefits in basic mechanisms of T helper
1 dominated autoimmune diseases, such as multi-
ple sclerosis, arthritis and Crohn’s disease.[218]
Other fields of research are disorders of blood pres-
sure[207,321] and antineoplastic activity.[154,322]
Cannabinoids seem to be able to control the cell
survival/death decision.[323] Thus, cannabinoids
may induce proliferation, growth arrest or apopto-
sis in a number of cells depending on dose.[323]
Several effects observed in animal studies provide
the basis for further research, among them effects
against diarrhoea in mice,[324] inhibition of bron-
chospasms provoked by chemical irritants in
rats[325] and stabilisation of respiration in sleep-re-
lated breathing disorders (e.g. apnoea).[326]
7. Drug Interactions
Interactions with other drugs may depend on ac-
tivity on similar effector systems or metabolic in-
teractions.[327]
Since cannabinoids are strongly bound to pro-
teins, interactions with other protein-bound drugs
may also occur. They might also interact with
drugs that, such as THC, are metabolised by en-
zymes of the CYP complex. However, there was
only a minor influence of cannabis smoking and
oral dronabinol on the pharmacokinetic parameters
of antiretroviral medications used in HIV infection
and metabolised by CYP enzymes, and the use of
cannabinoids is unlikely to affect antiretroviral ef-
ficacy.[328] Cessation of tobacco and cannabis
smoking was reported to result in elevated blood
concentrations of antipsychotic medication (cloza-
pine or olanzapine) due to cessation of induction
of CYP1A2 by smoke constituents.[329]
Other medicines may enhance or attenuate cer-
tain actions of THC, or certain actions of these
medicines may be enhanced or attenuated by
THC.[330,331] Moreover, it is possible that certain
effects are enhanced and others reduced, as is the
case with phenothiazines used against the adverse
effects of cancer chemotherapy. In a study by
Lane et al., a combination of prochlorperazine and
dronabinol was more effective in reducing un-
wanted effects of the antineoplastic medication
than the phenothiazine alone, and the incidence
of cannabinoid-induced adverse effects was de-
creased when dronabinol was combined with pro-
chlorperazine, which also has antipsychotic prop-
erties.[283] Cannabis, caffeine and tobacco reduced
the blood pressure reactivity protection of ascor-
bic acid, probably through their dopaminergic ef-
fects. [332]
Of greatest clinical relevance is reinforce-
ment of the sedating effect of other psychotropic
substances (alcohol, benzodiazepines), and the
interaction with substances that act on heart and
circulation (such as amphetamines, adrenaline, at-
ropine, β-blockers, diuretics and tricyclic antide-
pressants).[330,331]
A number of additive effects may be desirable,
such as the enhancement of muscle relaxants, bron-
chodilators and antiglaucoma medication,[210] the
analgesic effect of opioids,[333] the antiemetic ef-
fect of the phenothiazines[283] and the antiepileptic
action of benzodiazepines.[334] THC may antagon-
ise the antipsychotic actions of neuroleptics[331]
and may improve their clinical responsiveness in
motor disorders.[335]
Indomethacin, (aspirin (acetylsalicylic acid)
and other nonsteroidal anti-inflammatory drugs
antagonise the effects of THC. Indomethacin
significantly reduced subjective ‘high’,[336] tachy-
cardia[336] and decrease of intraocular pressure fol-
lowing topical THC (eye drops).[337] These inter-
actions reflect the fact that several THC effects
are at least in part mediated by prostaglandin-
mediated processes.[2,337]
8. Conclusions
The discovery, within the past 15 years, of a
system of specific cannabinoid receptors in hu-
mans and their endogenous ligands has strongly
350
Grotenhermen
© Adis International Limited. All rights reserved.
Clin Pharmacokinet 2003; 42 (4)

stimulated cannabinoid research, with about 650
articles published in Medline-listed journals in
2001 compared with about 250 in 1986. It has be-
come apparent that the endocannabinoid system
plays a major role in signal transduction in neuro-
nal cells, and arachidonylethanolamide (anandam-
ide) seems to be a central inhibitory compound in
the central nervous system.[338]
Mechanisms of action of cannabinoids are com-
plex, not only involving activation of and interac-
tion at the cannabinoid receptor, but also activation
of vanilloid receptors,[322] influence of endocan-
nabinoid concentration,[339] antioxidant activ-
ity,[142] metabolic interaction with other com-
pounds, and several others. There is still much to
learn about the physiological role of the natural
ligands for the CB receptor, about the long-term
effects of cannabis use, and even some controver-
sial findings on cannabinoid pharmacokinetics
remain to be solved. However, because of the
millennia-long use of cannabis for recreational, re-
ligious and medicinal purposes, which in recent
decades has been accompanied by research in
several disciplines, we do not expect to encounter
with the medicinal use of cannabinoids the same
unpleasant surprises that occasionally occur with
newly designed synthetic drugs.
Many people who suffer from severe illnesses
have discovered cannabis as a beneficial remedy,
and surveys in Europe and North America show
that increasing numbers of citizens in several
countries reject criminal prosecution of patients
who benefit from the drug. The psychotropic and
circulatory effects of CB1 receptor agonists and the
stigma of cannabis as a recreational and addicting
drug are still major obstacles to the legal therapeu-
tic utilisation of the whole range of potentially ben-
eficial effects. Properly designed and executed
clinical studies are necessary to verify anecdotal
experiences and the results from smaller uncon-
trolled studies, and to overcome uncertainties and
scepticism.
Aside from phytocannabinoids and cannabis
preparations, cannabinoid analogues that do not
bind to the CB1 receptor are attractive compounds
for clinical research, among them dexanabinol and
CT-3. Additional ideas for the separation of the
desired therapeutic effects from the psychotropic
actions comprise the concurrent administration of
THC and CBD, the design of CB1 receptor agonists
that do not cross the blood-brain barrier, and the
development of compounds that influence en-
docannabinoid levels by inhibition of their mem-
brane transport or hydrolysis. The future will show
which strategies prove successful and which drugs
will follow dronabinol and nabilone into the phar-
macy.
Acknowledgements
The author has provided no information on sources of
funding or on conflicts of interest directly relevant to the
content of this review.
References
1. Loewe S. Cannabiswirkstoffe und Pharmakologie der Can-
nabinole. Archiv Experimentelle Pathologie Pharmakologie
1950; 211: 175-93
2. Dewey WL. Cannabinoid pharmacology. Pharmacol Rev 1986;
38 (2): 151-78
3. Hollister LE. Health aspects of cannabis. Pharmacol Rev 1986;
38: 1-20
4. Gaoni Y, Mechoulam R. Isolation, structure and partial synthe-
sis of the active constituent of hashish. J Am Chem Soc 1964;
86: 1646-7
5. Devane WA, Dysarz III FA, Johnson MR, et al. Determination
and characterization of a cannabinoid receptor in rat brain.
Mol Pharmacol 1988; 34 (5): 605-13
6. Devane WA, Hanus L, Breuer A, et al. Isolation and structure
of a brain constituent that binds to the cannabinoid receptor.
Science 1992; 258 (5090): 1946-9
7. Razdan RK. Structure-activity relationships in cannabinoids.
Pharmacol Rev 1986; 38: 75-149
8. Pate D. Taxonomy of cannabinoids. In: Grotenhermen F, Russo
E, editors. Cannabis and cannabinoids: pharmacology, toxi-
cology, and therapeutic potential. Binghamton (NY):
Haworth Press, 2002: 15-26
9. ElSohly MA. Chemical constituents of cannabis. In: Grotenher-
men F, Russo E, editors. Cannabis and cannabinoids: phar-
macology, toxicology, and therapeutic potential. Binghamton
(NY): Haworth Press, 2002: 27-36
10. Field BI, Arndt RR. Cannabinoid compounds in South African
Cannabis sativa L. J Pharm Pharmacol 1980; 32 (1): 21-4
11. Pitts JE, Neal JD, Gough TA. Some features of Cannabis plants
grown in the United Kingdom from seeds of known origin. J
Pharm Pharmacol 1992; 44 (12): 947-51
12. Rowan MG, Fairbairn JW. Cannabinoid patterns in seedlings
of Cannabis sativa L. and their use in the determination of
chemical race. J Pharm Pharmacol 1977; 29 (8): 491-4
13. Harvey DJ. Characterization of the butyl homologues of delta1-
tetrahydrocannabinol, cannabinol and cannabidiol in samples
of cannabis by combined gas chromatography and mass spec-
trometry. J Pharm Pharmacol 1976; 28 (4): 280-5
Cannabinoids
351
© Adis International Limited. All rights reserved.
Clin Pharmacokinet 2003; 42 (4)

14. Vree TB, Breimer DD, van Ginneken CA, et al. Identification
in hashish of tetrahydrocannabinol, cannabidiol and cannabi-
nol analogues with a methyl side-chain. J Pharm Pharmacol
1972; 24 (1): 7-12
15. ElSohly MA, Ross SA, Mehmedic Z, et al. Potency trends of
Δ9-THC and other cannabinoids in confiscated marijuana
from 1980-1997. J Forensic Sci 2000; 45 (1): 24-30
16. Brenneisen R. Psychotrope drogen: II. Bestimmung der Can-
nabinoide in Cannabis sativa L. und in Cannabisprodukten
mittels Hochdruckflüssigkeitschromatographie (HPLC).
Pharm Acta Helv 1984; 59: 247-59
17. Baker PB, Taylor BJ, Gough TA. The tetrahydrocannabinol and
tetrahydrocannabinolic acid content of cannabis products. J
Pharm Pharmacol 1981; 33 (6): 369-72
18. Garrett ER, Hunt CA. Physiochemical properties, solubility,
and protein binding of Δ9-tetrahydrocannabinol. J Pharm Sci
1974; 63 (7): 1056-64
19. Mechoulam R. Chemistry of cannabis. Handbook Exp Phar-
macol 1981; 53: 119-34
20. Thomas BF, Compton DR, Martin BR. Characterization of the
lipophilicity of natural and synthetic analogs of delta 9-tetra-
hydrocannabinol and its relationship to pharmacological po-
tency. J Pharmacol Exp Ther 1990; 255 (2): 624-30
21. Johnson JR, Jennison TA, Peat MA, et al. Stability of delta
9-tetrahydrocannabinol (THC), 11-hydroxy-THC, and 11-
nor-9-carboxy-THC in blood and plasma. J Anal Toxicol
1984; 8 (5): 202-4
22. NN Monographs: Dronabinol capsules 2.5/5 or 10mg (NRF
22.7.); oily dronabinol drops 2.5% (NRF 22.8). In: Bun-
desvereinigung Deutscher Apothekerverbände, editor. Neues
Rezepturformularium (NRF), Loose-Leaf Collection of 2001.
Eschborn, Germany: Govi-Verlag Pharmazeutischer Verlag /
Stuttgart, Germany: Deutscher Apotheker-Verlag, 2001
23. Agurell S, Leander K. Stability, transfer and absorption of can-
nabinoid constituents of cannabis (hashish) during smoking.
Acta Pharm Suec 1971; 8 (4): 391-402
24. Fairbairn JW, Liebmann JA, Rowan MG. The stability of can-
nabis and its preparations on storage. J Pharm Pharmacol
1976; 28: 1-7
25. Brenneisen R, Egli A, Elsohly MA, et al. The effect of orally
and rectally administered delta 9-tetrahydrocannabinol on
spasticity: a pilot study with 2 patients. Int J Clin Pharmacol
Ther 1996; 34 (10): 446-52
26. Stinchcomb A, Challapalli P, Harris K, et al. Optimization of in
vitro experimental conditions for measuring the percutaneous
absorption of Δ9-THC, cannabidiol, and WIN55,212-2 [ab-
stract]. 2001 Symposium on the Cannabinoids. Burlington
(VT): International Cannabinoid Research Society, 2001: 161
27. Guy GW, Flint ME. A phase one study of sublingual Cannabis
based medicinal extracts. 2000 Symposium on the Can-
nabinoids. Burlington (VT): International Cannabinoid Re-
search Society: 2000, 115
28. Merritt JC, Olsen JL, Armstrong JR, et al. Topical delta 9-tet-
rahydrocannabinol in hypertensive glaucomas. J Pharm Phar-
macol 1981; 33 (1): 40-1
29. Lichtman AH, Peart J, Poklis JL, et al. Pharmacological evalu-
ation of aerosolized cannabinoids in mice. Eur J Pharmacol
2000; 399 (2-3): 141-9
30. Williams SJ, Hartley JP, Graham JD. Bronchodilator effect of
delta1-tetrahydrocannabinol administered by aerosol of asth-
matic patients. Thorax 1976; 31 (6): 720-3
31. Wall ME, Sadler BM, Brine D, et al. Metabolism, disposition,
and kinetics of delta-9-tetrahydrocannabinol, in men and
women. Clin Pharmacol Ther 1983; 34 (3): 352-63
32. Hunt CA. Jones RT. Tolerance and disposition of tetrahydro-
cannabinol in man. J Pharmacol Exp Ther 1980; 215 (1):
35-44
33. Kelly P, Jones RT. Metabolism of tetrahydrocannabinol in fre-
quent and infrequent marijuana users. J Anal Toxicol 1992;
16 (4): 228-35
34. Brenneisen R. Pharmakokinetik. In: Grotenhermen F, editor.
Cannabis und Cannabinoide. Pharmakologie, Toxikologie
und Therapeutisches Potenzial. Göttingen: Hans Huber Ver-
lag, 2001: 87-92
35. Huestis MA, Henningfield JE, Cone EJ. Blood cannabinoids: I.
absorption of THC and formation of 11-OH-THC and
THCCOOH during and after smoking marijuana. J Anal Tox-
icol 1992; 16 (5): 276-82
36. Chiang CW, Barnett G. Marijuana effect and delta-9-tetrahy-
drocannabinol plasma level. Clin Pharmacol Ther 1984; 36
(2): 234-8
37. Hollister LE, Gillespie HK, Ohlsson A, et al. Do plasma con-
centrations of delta 9-tetrahydrocannabinol reflect the degree
of intoxication? J Clin Pharmacol 1981; 21 (8-9 Suppl.):
171S-7S
38. Lindgren JE, Ohlsson A, Agurell S, et al. Clinical effects and
plasma levels of delta 9-tetrahydrocannabinol (delta 9-THC)
in heavy and light users of cannabis. Psychopharmacology
1981; 74 (3): 208-12
39. Ohlsson A, Lindgren JE, Wahlen A, et al. Plasma delta-9 tetra-
hydrocannabinol concentrations and clinical effects after oral
and intravenous administration and smoking. Clin Pharmacol
Ther 1980; 28 (3): 409-16
40. Perez-Reyes M, Di Guiseppi S, Davis KH, et al. Comparison of
effects of marihuana cigarettes to three different potencies.
Clin Pharmacol Ther 1982; 31 (5): 617-24
41. Sporkert F, Pragst F, Ploner CJ, et al. Pharmacokinetic investi-
gation of delta-9-tetrahydrocannabinol and its metabolites af-
ter single administration of 10mg Marinol in attendance of a
psychiatric study with 17 volunteers. Poster at the 39th An-
nual International Meeting, International Association of Fo-
rensic Toxicologists; 2001 Aug 26-30; Prague, Czech
Republic
42. Ohlsson A, Lindgren JE, Wahlen A, et al. Single dose kinetics
of deuterium labelled Δ1-tetrahydrocannabinol in heavy and
light cannabis users. Biomed Mass Spectrom 1982; 9 (1): 6-10
43. Davis KH, McDaniell JA, Cadwell LW, et al. Some smoking
characteristics of marijuana cigarettes. In: Agurell S, Dewey
WL, Willette RE, editors. The cannabinoids: chemical, phar-
macologic and therapeutic aspects. New York: Academic
Press, 1984: 245-61
44. Timpone JG, Wright DJ, Li N, et al. The safety and pharmaco-
kinetics of single-agent and combination therapy with
megestrol acetate and dronabinol for the treatment of HIV
wasting syndrome. AIDS Res Hum Retroviruses 1997; 13 (4):
305-15
45. Law B, Mason PA, Moffat AC, et al. Forensic aspects of the
metabolism and excretion of cannabinoids following oral in-
gestion of cannabis resin. J Pharm Pharmacol 1984; 36 (5):
289-94
46. Frytak S, Moertel CG, Rubin J. Metabolic studies of delta-9-tet-
rahydrocannabinol in cancer patients. Cancer Treat Rep 1984;
68 (12): 1427-31
47. Harvey DJ. Metabolism and pharmacokinetics of the can-
nabinoids. In: Watson RR, editor. Biochemistry and physiol-
ogy of substance abuse. Vol III. Boca Raton (FL): CRC Press,
1991: 279-365
352
Grotenhermen
© Adis International Limited. All rights reserved.
Clin Pharmacokinet 2003; 42 (4)

48. Lemberger L, Weiss JL, Watanabe AM, et al. Delta-9-tetrahy-
drocannabinol. Temporal correlation of the psychologic ef-
fects and blood levels after various routes of administration.
N Engl J Med 1972; 286 (13): 685-8
49. Chiang CW, Barnett G, Brine D. Systemic absorption of delta
9-tetrahydrocannabinol after ophthalmic administration to
the rabbit. J Pharm Sci 1983; 72 (2): 136-8
50. ElSohly MA, Stanford DF, Harland EC, et al. Rectal bioavail-
ability of delta-9-tetrahydrocannabinol from the hemisuccin-
ate ester in monkeys. J Pharm Sci 1991; 80 (10): 942-5
51. Notcutt W, Price M, Miller R, et al. Medicinal cannabis extracts
in chronic pain: (5) cognitive function and blood cannabinoid
levels. 2001 Congress on Cannabis and the Cannabinoids.
Cologne, Germany: International Association for Cannabis
as Medicine; 28
52. Touitou E, Fabin B, Dany S, et al. Transdermal delivery of
tetrahydrocannabinol. Int J Pharm 1988; 43: 9-15
53. Leuschner JT, Harvey DJ, Bullingham RE, et al. Pharmacoki-
netics of delta 9-tetrahydrocannabinol in rabbits following
single or multiple intravenous doses. Drug Metab Dispos
1986; 14 (2): 230-8
54. Widman M, Agurell S, Ehrnebo M, et al. Binding of (+)- and
(–)-Δ1- tetrahydrocannabinols and (–)-7-hydroxy-Δ1-tetra-
hydrocannabinol to blood cells and plasma proteins in man.
J Pharm Pharmacol 1974; 26 (11): 914-6
55. Fehr KO, Kalant H. Fate of 14C-delta1-THC in rat plasma after
intravenous injection and smoking. Eur J Pharmacol 1974; 25
(1): 1-8
56. Wahlqvist M, Nilsson IM, Sandberg F, et al. Binding of delta-
1-tetrahydrocannabinol to human plasma proteins. Biochem
Pharmacol 1970; 19 (9): 2579-84
57. Lemberger L, Tamarkin NR, Axelrod J, et al. Delta-9-tetrahy-
drocannabinol: metabolism and disposition in long-term ma-
rihuana smokers. Science 1971; 173 (991): 72-4
58. Barnett G, Chiang CW, Perez-Reyes M, et al. Kinetic study of
smoking marijuana. J Pharmacokinet Biopharm 1982; 10 (5):
495-506
59. Brewster ME, Pop E, Foltz RL, et al. Clinical pharmacokinetics
of escalating i.v. doses of dexanabinol (HU-211), a neu-
roprotectant agent, in normal volunteers. Int J Clin Pharmacol
Ther 1997; 35 (9): 361-5
60. Sticht G, Käferstein H. Grundbegriffe, toxikokinetik und tox-
ikodynamik. In: Berghaus G, Krüger HP, editors. Cannabis
im Straßenverkehr. Stuttgart: Gustav Fischer, 1998: 1-11
61. Ryrfeldt A, Ramsay CH, Nilsson IM, et al. Whole-body auto-
radiography of Δ1-tetrahydrocannabinol and Δ1 (6)-tetrahy-
drocannabinol in mouse: pharmacokinetic aspects of
Δ1-tetrahydrocannabinol and its metabolites. Acta Pharm
Suec 1973; 10 (1): 13-28
62. Ho BT, Fritchie GE, Kralik PM, et al. Distribution of tritiated-1
delta 9-tetrahydrocannabinol in rat tissues after inhalation. J
Pharm Pharmacol 1970; 22 (7): 538-9
63. Gill EW, Jones G. Brain levels of Δ1-tetrahydrocannabinol and
its metabolites in mice: correlation with behaviour, and the
effect of the metabolic inhibitors SKF 525A and piperonyl
butoxide. Biochem Pharmacol 1972; 21 (16): 2237-48
64. Chiang CN, Rapaka RS. Pharmacokinetics and disposition of
cannabinoids. NIDA Res Monogr 1987; 79: 173-88
65. Perez-Reyes M, Simmons J, Brine D, et al. Rate of penetration
of Δ9-tetrahydrocannabinol and 11-hydroxy-Δ9-tetrahydro-
cannabinol to the brain of mice. In: Nahas GG, editor. Mari-
huana: chemistry, biochemistry, and cellular effects. New
York: Springer, 1976: 179-85
66. Agurell S, Nilsson IM, Ohlsson A, et al. On the metabolism of
tritium-labelled, 1-tetrahydrocannabinol in the rabbit.
Biochem Pharmacol 1970; 19 (4): 1333-9
67. Johansson E, Noren K, Sjovall J, et al. Determination of delta
1-tetrahydrocannabinol in human fat biopsies from mari-
huana users by gas chromatography-mass spectrometry.
Biomed Chromatogr 1989; 3 (1): 35-8
68. Kreuz DS, Axelrod J. Delta-9-tetrahydrocannabinol: localiza-
tion in body fat. Science 1973; 179 (71): 391-3
69. Harvey DJ, Leuschner JT, Paton WD. Gas chromatographic
and mass spectrometric studies on the metabolism and phar-
macokinetics of delta 1-tetrahydrocannabinol in the rabbit. J
Chromatogr 1982; 239: 243-50
70. Haggerty GC, Deskin R, Kurtz PJ, et al. The pharmacological
activity of the fatty acid conjugate 11-palmitoyloxy-delta 9-
tetrahydrocannabinol. Toxicol Appl Pharmacol 1986; 84 (3):
599-606
71. Leighty EG, Fentiman Jr AF, Foltz RL. Long-retained metabo-
lites of Δ9- and Δ8-tetrahydrocannabinols identified as novel
fatty acid conjugates. Res Commun Chem Pathol Pharmacol
1976; 14 (1): 13-28
72. Blackard C, Tennes K. Human placental transfer of can-
nabinoids [letter]. N Engl J Med 1984; 311: 797
73. Abrams RM, Cook CE, Davis KH, et al. Plasma delta-9-tetra-
hydrocannabinol in pregnant sheep and fetus after inhalation
of smoke from a marijuana cigarette. Alcohol Drug Res 1985-
1986; 6: 361-9
74. Bailey JR, Cunny HC, Paule MG, et al. Fetal disposition of delta
9-tetrahydrocannabinol (THC) during late pregnancy in the
rhesus monkey. Toxicol Appl Pharmacol 1987; 90: 315-21
75. Hutchings DE, Martin BR, Gamagaris Z, et al. Plasma concen-
trations of delta-9-tetrahydrocannabinol in dams and fetuses
following acute or multiple prenatal dosing in rats. Life Sci
1989; 44 (11): 697-701
76. Martin BR, Dewey WL, Harris LS, et al. 3H-delta 9-tetrahydro-
cannabinol distribution in pregnant dogs and their fetuses.
Res Commun Chem Pathol Pharmacol 1977; 17: 457-70
77. Boskovic R, Klein J, Woodland C, et al. The role of the placenta
in variability of fetal exposure to cocaine and cannabinoids:
a twin study. Can J Physiol Pharmacol 2001; 79 (11): 942-5
78. Chao FC, Green DE, Forrest IS, et al. The passage of 14C-delta-
9-tetrahydrocannabinol into the milk of lactating squirrel
monkeys. Res Commun Chem Pathol Pharmacol 1976; 15:
303-17
79. Perez-Reyes M, Wall ME. Presence of delta 9-tetrahydrocan-
nabinol in human milk. N Engl J Med 1982; 307: 819-20
80. Matsunaga T, Iwawaki Y, Watanabe K, et al. Metabolism of
delta 9-tetrahydrocannabinol by cytochrome P450 isozymes
purified from hepatic microsomes of monkeys. Life Sci 1995;
56 (23-24): 2089-95
81. Narimatsu S, Watanabe K, Matsunaga T, et al. Cytochrome
P-450 isozymes involved in the oxidative metabolism of delta
9-tetrahydrocannabinol by liver microsomes of adult female
rats. Drug Metab Dispos 1992; 20 (1): 79-83
82. Watanabe K, Matsunaga T, Yamamoto I, et al. Involvement of
CYP2C in the metabolism of cannabinoids by human hepatic
microsomes from an old woman. Biol Pharm Bull 1995; 18
(8): 1138-41
83. Alozie SO, Martin BR, Harris LS, et al. 3H-delta 9-Tetrahydro-
cannabinol, 3H-cannabinol and 3H-cannabidiol: penetration
and regional distribution in rat brain. Pharmacol Biochem
Behav 1980; 12 (2): 217-21
84. Borys HK, Karler R. Cannabidiol and delta 9-tetrahydrocan-
nabinol metabolism: in vitro comparison of mouse and rat
Cannabinoids
353
© Adis International Limited. All rights reserved.
Clin Pharmacokinet 2003; 42 (4)

liver crude microsome preparations. Biochem Pharmacol
1979; 28 (9): 1553-9
85. Harvey DJ, Brown NK. Comparative in vitro metabolism of
the cannabinoids. Pharmacol Biochem Behav 1991; 40 (3):
533-40
86. Grotenhermen F. Review of unwanted actions of cannabis and
THC. In: Grotenhermen F, Russo E, editors. Cannabis and
cannabinoids: pharmacology, toxicology, and therapeutic po-
tential. Binghamton (NY): Haworth Press, 2002: 233-48
87. Harvey DJ, Paton WDM. Examination of the metabolites of
Δ1-tetrahydrocannabinol in mouse, liver, heart and lung by
combined gas chromatography and mass spectrometry. In:
Nahas GG, editor. Marihuana: chemistry, biochemistry and
cellular effects. New York: Springer-Verlag, 1976: 93-107
88. Nakazawa K, Costa E. Metabolism of delta 9-tetrahydrocannab-
inol by lung and liver homogenates of rats treated with
methylcholanthrene. Nature 1971; 234 (5323): 48-9
89. Widman M, Nordqvist M, Dollery CT, et al. Metabolism of
delta1-tetrahydrocannabinol by the isolated perfused dog
lung. Comparison with in vitro liver metabolism. J Pharm
Pharmacol 1975; 27 (11): 842-8
90. Wall ME. The in vivo and in vitro metabolism of tetrahydro-
cannabinol. Ann N Y Acad Sci 1971; 191: 23-9
91. Widman M, Halldin M, Martin B. In vitro metabolism of tetra-
hydrocannabinol by rhesus monkey liver and human liver.
Adv Biosci 1978; 22-23: 101-3
92. Leighty EG. Metabolism and distribution of cannabinoids in
rats after different methods of administration. Biochem Phar-
macol 1973; 22 (13): 1613-21
93. Johansson E, Halldin MM, Agurell S, et al. Terminal elimina-
tion plasma half-life of delta 1-tetrahydrocannabinol (delta
1-THC) in heavy users of marijuana. Eur J Clin Pharmacol
1989; 37 (3): 273-7
94. Schwartz RH, Hayden GF, Riddile M. Laboratory detection of
marijuana use: experience with a photometric immunoassay
to measure urinary cannabinoids. Am J Dis Child 1985; 139
(11): 1093-6
95. Ellis Jr GM, Mann MA, Judson BA, et al. Excretion patterns of
cannabinoid metabolites after last use in a group of chronic
users. Clin Pharmacol Ther 1985; 38 (5): 572-8
96. Huestis MA, Cone EJ. Urinary excretion half-life of 11-nor-9-
carboxy-Δ9-tetrahydrocannabinol in humans. Ther Drug
Monit 1998; 20 (5): 570-6
97. Johansson E, Halldin MM. Urinary excretion half-life of delta
1-tetrahydrocannabinol-7-oic acid in heavy marijuana users
after smoking. J Anal Toxicol 1989; 13 (4): 218-23
98. Halldin MM, Andersson LK, Widman M, et al. Further urinary
metabolites of delta 1-tetrahydrocannabinol in man. Arz-
neimittel Forschung 1982; 32 (9): 1135-8
99. Halldin MM, Carlsson S, Kanter SL, et al. Urinary metabolites
of delta 1-tetrahydrocannabinol in man. Arzneimittel Fors-
chung 1982; 32 (7): 764-8
100. Williams PL, Moffat AC. Identification in human urine of delta
9-tetrahydrocannabinol-11-oic acid glucuronide: a tetrahy-
drocannabinol metabolite. J Pharm Pharmacol 1980; 32 (7):
445-8
101. Alburges ME, Peat MA. Profiles of delta 9-tetrahydrocannab-
inol metabolites in urine of marijuana users: preliminary
observations by high performance liquid chromatography-
radioimmunoassay. J Forensic Sci 1986; 31 (2): 695-706
102. Wall ME, Perez-Reyes M. The metabolism of delta 9-tetrahy-
drocannabinol and related cannabinoids in man. J Clin Phar-
macol 1981; 21 (8-9 Suppl.): 178S-89S
103. Manno JE, Manno BR, Kemp PM, et al. Temporal indication
of marijuana use can be estimated from plasma and urine
concentrations of Δ9-tetrahydrocannabinol, 11-hydroxy-Δ9-
tetrahydrocannabinol, and 11-nor-Δ9-tetrahydrocannabinol-
9-carboxylic acid. J Anal Toxicol 2001; 25 (7): 538-49
104. Mikes F, Hofmann A, Waser PG. Identification of (-)-delta 9-
6a,10a-trans-tetrahydrocannabinol and two of its metabolites
in rats by use of combination gas chromatography-mass spec-
trometry and mass fragmentography. Biochem Pharmacol
1971; 20 (9): 2469-76
105. Harder S, Rietbrock S. Concentration-effect relationship of
delta-9-tetrahydrocannabiol and prediction of psychotropic
effects after smoking marijuana. Int J Clin Pharmacol Ther
1997; 35 (4): 155-9
106. Robbe HWJ. Influence of marijuana on driving. Maastricht:
Institut for Human Psychopharmacology, University of Lim-
burg, 1994
107. Barnett G, Licko V, Thompson T. Behavioral pharmacokinetics
of marijuana. Psychopharmacology 1985; 85 (1): 51-6
108. Cocchetto DM, Owens SM, Perez-Reyes M, et al. Relationship
between plasma delta-9-tetrahydrocannabinol concentration
and pharmacologic effects in man. Psychopharmacology
1981; 75 (2): 158-64
109. Nyoni EC, Sitaram BR, Taylor DA. Determination of delta
9-tetrahydrocannabinol levels in brain tissue using high-per-
formance liquid chromatography with electrochemical detec-
tion. J Chromatogr B Biomed Appl 1996; 679 (1-2): 79-84
110. McIsaac W, Fritchie G, Idanpaan-Heikkila J, et al. Distribution
of marihuana in monkey brain and concomitant behavioural
effects. Nature 1971; 230 (5296): 593-4
111. Ohlsson A, Widman M, Carlsson S, et al. Plasma and brain
levels of delta 6-THC and seven monooxygenated metabo-
lites correlated to the cataleptic effect in the mouse. Acta
Pharmacol Toxicol (Copenh); 1980; 47 (4): 308-17
112. Law B, Moffat AC. The influence of the metabolism and elim-
ination of cannabinoids on forensic analysis and interpreta-
tion. In: Harvey DJ, editor. Marijuana ‘84: Proceedings of the
Oxford Symposium on Cannabis. Oxford: IRL Press Limited,
1985: 197-204
113. McBurney LJ, Bobbie BA, Sepp LA. GC/MS and EMIT anal-
yses for delta 9-tetrahydrocannabinol metabolites in plasma
and urine of human subjects. J Anal Toxicol 1986; 10 (2):
56-64
114. Daldrup TH. Cannabis im Straßenverkehr. Final report commis-
sioned by the Ministry of Economy, Technology and Traffic
of North Rhine-Westphalia. Düsseldorf: University of
Düsseldorf, 1996
115. Hanson V, Buonarati M, Baselt R, et al. Comparison of 3H- and
125I-radioimmunoassay and gas chromatography/mass spec-
trometry for the determination of Δ9-tetrahydrocannabinol
and cannabinoids in blood and serum. J Anal Toxicol 1983;
7: 96-102
116. Huestis MA, Henningfield JE, Cone EJ. Blood cannabinoids:
II. models for the prediction of time of marijuana exposure
from plasma concentrations of delta 9-tetrahydrocannabinol
(THC) and 11-nor-9-carboxy-delta 9-tetrahydrocannabinol
(THCCOOH). J Anal Toxicol 1992; 16 (5): 283-90
117. Agurell S, Halldin M, Lindgren JE, et al. Pharmacokinetics and
metabolism of delta 1-tetrahydrocannabinol and other can-
nabinoids with emphasis on man. Pharmacol Rev 1986; 38
(1): 21-43
118. Ohlsson A, Lindgren JE, Andersson S, et al. Single dose ki-
netics of cannabidiol in man. In: Agurell S, Dewey WL,
Willette R, editors. The cannabinoids: chemical, pharma-
354
Grotenhermen
© Adis International Limited. All rights reserved.
Clin Pharmacokinet 2003; 42 (4)

cologic, and therapeutic aspects. New York: Academic Press,
1984: 219-25
119. Agurell S, Carlsson S, Lindgren JE, et al. Interactions of delta
1-tetrahydrocannabinol with cannabinol and cannabidiol fol-
lowing oral administration in man: assay of cannabinol and
cannabidiol by mass fragmentography. Experientia 1981; 37
(10): 1090-2
120. Consroe P, Laguna J, Allender J, et al. Controlled clinical trial
of cannabidiol in Huntington’s disease. Pharmacol Biochem
Behav 1991; 40 (3): 701-8
121. Harvey DJ, Mechoulam R. Metabolites of cannabidiol identi-
fied in human urine. Xenobiotica 1990; 20 (3): 303-20
122. Wall ME, Brine DR, Perez-Reyes M. Metabolism of can-
nabinoids in man. In: Braude MC, Szara S, editors. Pharma-
cology of marihuana. New York: Raven Press, 1976: 93-113
123. Lemberger L, Rubin A, Wolen R, et al. Pharmacokinetics, me-
tabolism and drug-abuse potential of nabilone. Cancer Treat
Rev 1982; 9 Suppl. B: 17-23
124. Rubin A, Lemberger L, Warrick P, et al. Physiologic disposi-
tion of nabilone, a cannabinol derivative, in man. Clin Phar-
macol Ther 1977; 22 (1): 85-91
125. Sullivan HR, Kau DL, Wood PG. Pharmacokinetics of
nabilone, a psychotropically active 9-ketocannabinoid, in
the dog. Utilization of quantitative selected ion monitoring
and deuterium labeling. Biomed Mass Spectrom 1978; 5
(4): 296-301
126. Sullivan HR, Hanasono GK, Miller WM, et al. Species spec-
ificity in the metabolism of nabilone: relationship between
toxicity and metabolic routes. Xenobiotica 1987; 17 (4):
459-68
127. Bornheim LM, Grillo MP. Characterization of cytochrome
P450 3A inactivation by cannabidiol: possible involvement
of cannabidiol-hydroxyquinone as a P450 inactivator. Chem
Res Toxicol 1998; 11 (10): 1209-16
128. Jaeger W, Benet LZ, Bornheim LM. Inhibition of cyclosporine
and tetrahydrocannabinol metabolism by cannabidiol in
mouse and human microsomes. Xenobiotica 1996; 26 (3):
275-84
129. Watanabe K, Arai M, Narimatsu S, et al. Self-catalyzed inacti-
vation of cytochrome P-450 during microsomal metabolism
of cannabidiol. Biochem Pharmacol 1987; 36 (20): 3371-7
130. Yamamoto I, Watanabe K, Narimatsu S, et al. Recent advances
in the metabolism of cannabinoids. Int J Biochem Cell Biol
1995; 27 (8): 741-6
131. Bornheim LM, Kim KY, Li J, et al. Effect of cannabidiol pre-
treatment on the kinetics of tetrahydrocannabinol metabolites
in mouse brain. Drug Metab Dispos 1995; 23 (8): 825-31
132. Hunt CA, Jones RT, Herning RI, et al. Evidence that cannabi-
diol does not significantly alter the pharmacokinetics of tet-
rahydrocannabinol in man. J Pharmacokinet Biopharm 1981;
9 (3): 245-60
133. Bornheim LM, Everhart ET, Li J, et al. Induction and genetic
regulation of mouse hepatic cytochrome P450 by cannabi-
diol. Biochem Pharmacol 1994; 48 (1): 161-71
134. Watanabe K, Arai M, Narimatsu S, et al. Effect of repeated
administration of 11-hydroxy-delta 8-tetrahydrocannabinol,
an active metabolite of delta 8-tetrahydrocannabinol, on the
hepatic microsomal drug-metabolizing enzyme system of
mice. Biochem Pharmacol 1986; 35 (11): 1861-5
135. Costa B, Parolaro D, Colleoni M. Chronic cannabinoid, CP-
55,940, administration alters biotransformation in the rat. Eur
J Pharmacol 1996; 313 (1-2): 17-24
136. Hollister LE, Gillespie H. Interactions in man of delta-9-tetra-
hydrocannabinol: II. cannabinol and cannabidiol. Clin Phar-
macol Ther 1975; 18 (1): 80-3
137. Zuardi AW, Shirakawa I, Finkelfarb E, et al. Action of canna-
bidiol on the anxiety and other effects produced by delta 9-
THC in normal subjects. Psychopharmacology 1982; 76 (3):
245-50
138. Karniol IG, Shirakawa I, Kasinski N, et al. Cannabidiol inter-
feres with the effects of delta 9-tetrahydrocannabinol in man.
Eur J Pharmacol 1974; 28 (1): 172-7
139. Petitet F, Jeantaud B, Reibaud M, et al. Complex pharmacology
of natural cannabinoids: evidence for partial agonist activity
of Δ9-tetrahydrocannabinol and antagonist activity of canna-
bidiol on rat brain cannabinoid receptors. Life Sci 1998; 63
(1): PL1-6
140. De Petrocellis L, Melck D, Bisogno T, et al. Finding of the
endocannabinoid signalling system in Hydra, a very primitive
organism: possible role in the feeding response. Neuroscience
1999; 92 (1): 377-87
141. Bueb JL, Lambert DM, Tschirhart EJ. Receptor-independent
effects of natural cannabinoids in rat peritoneal mast cells in
vitro. Biochim Biophys Acta 2001; 1538 (2-3): 252-9
142. Hampson A. Cannabinoids as neuroprotectants against isch-
emia. In: Grotenhermen F, Russo E, editors. Cannabis and
cannabinoids: pharmacology, toxicology, and therapeutic po-
tential. Binghamton (NY): Haworth Press, 2002: 101-10
143. Ralevic V, Kendall DA. Cannabinoids inhibit pre- and
postjunctionally sympathetic neurotransmission in rat mesen-
teric arteries. Eur J Pharmacol 2002; 444 (3): 171-81
144. Abrahamov A, Abrahamov A, Mechoulam R. An efficient new
cannabinoid antiemetic in pediatric oncology. Life Sci 1995;
56 (23-24): 2097-102
145. Pertwee RG. Pharmacology of cannabinoid CB1 and CB2 re-
ceptors. Pharmacol Ther 1997; 74 (2): 129-80
146. Pertwee RG. Sites and mechanisms of action. In: Grotenhermen
F, Russo E, editors. Cannabis and cannabinoids: pharmacol-
ogy, toxicology, and therapeutic potential. Binghamton
(NY): Haworth Press, 2002: 73-88
147. Schweitzer P. Cannabinoids decrease the K+ M-current in hip-
pocampal CA1 neurons. J Neurosci 2000; 20: 51-8
148. Glass M, Felder CC. Concurrent stimulation of cannabinoid
CB1 and dopamine D2 receptors augments cAMP accumula-
tion in striatal neurons: evidence for a Gs linkage to the CB1
receptor. J Neurosci 1997; 17: 5327-33
149. Galiègue S, Mary S, Marchand J, et al. Expression of central
and peripheral cannabinoid receptors in human immune tis-
sues and leukocyte subpopulations. Eur J Biochem 1995; 232:
54-61
150. Breivogel CS, Griffin G, Di Marzo V, et al. Evidence for a new
G protein-coupled cannabinoid receptor in mouse brain. Mol
Pharmacol 2001; 60 (1): 155-63
151. Di Marzo V, Breivogel CS, Tao Q, et al. Levels, metabolism,
and pharmacological activity of anandamide in CB (1) can-
nabinoid receptor knockout mice: evidence for non-CB (1),
non-CB (2) receptor-mediated actions of anandamide in
mouse brain. J Neurochem 2000; 75 (6): 2434-44
152. Pertwee RG. Evidence for the presence of CB1 cannabinoid
receptors on peripheral neurones and for the existence of
neuronal non-CB1 cannabinoid receptors. Life Sci 1999;
65: 597-605
153. Recht LD, Salmonsen R, Rosetti R, et al. Antitumor effects of
ajulemic acid (CT3), a synthetic non-psychoactive can-
nabinoid. Biochem Pharmacol 2001; 62 (6): 755-63
Cannabinoids
355
© Adis International Limited. All rights reserved.
Clin Pharmacokinet 2003; 42 (4)

154. Sanchez C, de Ceballos ML, del Pulgar TG, et al. Inhibition of
glioma growth in vivo by selective activation of the CB2 can-
nabinoid receptor. Cancer Res 2001; 61 (15): 5784-9
155. Giuffrida A, Beltramo M, Piomelli D. Mechanisms of en-
docannabinoid inactivation: biochemistry and pharmacology.
J Pharmacol Exp Ther 2001; 298 (1): 7-14
156. Sugiura T, Kondo S, Sukagawa A, et al. 2-Arachidonoyl-
glycerol: a possible endogenous cannabinoid receptor
ligand in brain. Biochem Biophys Res Commun 1995; 215
(1): 89-97
157. De Petrocellis L, Melck D, Bisogno T, et al.  Endocannabinoids
and fatty acid amides in cancer, inflammation and related
disorders. Chem Phys Lipids 2000; 108 (1-2): 191-209
158. Di Marzo V. ‘Endocannabinoids’ and other fatty acid deriva-
tives with cannabimimetic properties: biochemistry and pos-
sible physiopathological relevance. Biochim Biophys Acta
1998; 1392 (2-3): 153-75
159. Cravatt BF, Demarest K, Patricelli MP, et al. Supersensitivity
to anandamide and enhanced endogenous cannabinoid signal-
ing in mice lacking fatty acid amide hydrolase. Proc Natl
Acad Sci U S A 2001; 98 (16): 9371-6
160. Abadji V, Lin S, Gihan T, et al. (R)-Methanandamide: a chiral
novel anandamide possessing higher potency and metabolic
stability. J Med Chem 1994; 37: 1889-93
161. Pertwee RG. Pharmacology of cannabinoid receptor ligands.
Curr Med Chem 1999; 6: 635-64
162. Walker JM, Huang SM, Strangman NM, et al. Pain modulation
by release of the endogenous cannabinoid anandamide. Proc
Natl Acad Sci U S A 1999; 96 (21): 12198-203
163. Baker D, Pryce G, Croxford JL, et al. Endocannabinoids control
spasticity in a multiple sclerosis model. FASEB J 2001; 15
(2): 300-2
164. Siegling A, Hofmann HA, Denzer D, et al. Cannabinoid CB1
receptor upregulation in a rat model of chronic neuropathic
pain. Eur J Pharmacol 2001; 415 (1): R5-7
165. Izzo AA, Fezza F, Capasso R, et al. Cannabinoid CB1-receptor
mediated regulation of gastrointestinal motility in mice in a
model of intestinal inflammation. Br J Pharmacol 2001; 134
(3): 563-70
166. Di Marzo V, Goparaju SK, Wang L, et al. Leptin-regulated
endocannabinoids are involved in maintaining food intake.
Nature 2001; 410 (6830): 822-5
167. Darmani NA. Delta-9-tetrahydrocannabinol differentially sup-
presses cisplatin-induced emesis and indices of motor func-
tion via cannabinoid CB (1) receptors in the least shrew.
Pharmacol Biochem Behav 2001; 69 (1-2): 239-49
168. Leweke FM, Giuffrida A, Wurster U, et al. Elevated endoge-
nous cannabinoids in schizophrenia. Neuroreport 1999; 10
(8): 1665-9
169. Beaulieu P, Bisogno T, Punwar S, et al. Role of the endogenous
cannabinoid system in the formalin test of persistent pain in
the rat. Eur J Pharmacol 2000; 396 (2-3): 85-92
170. Adams IB, Martin BR. Cannabis: pharmacology and toxicology
in animals and humans. Addiction 1996; 91 (11): 1585-614
171. Grotenhermen F, Russo E, editors. Cannabis and cannabinoids.
Pharmacology, toxicology, and therapeutic potential. Bing-
hamton (NY): Haworth Press, 2002
172. Hall W, Solowij N, Lemon J. The health and psychological
consequences of cannabis use. Canberra: Commonwealth De-
partment of Human Services and Health, Monograph Series
No. 25, 1994
173. House of Lords Select Committee on Science and Technology.
Cannabis: the scientific and medical evidence. London: The
Stationery Office, 1998
174. Joy JE, Watson SJ, Benson JA, editors. Marijuana and medi-
cine: assessing the science base. Washington, DC: Institute of
Medicine, National Academy Press, 1999
175. Kalant H, Corrigal W, Hall W, et al., editors. The health effects
of cannabis. Toronto (ON): Centre for Addiction and Mental
Health, 1999
176. Sulcova E, Mechoulam R, Fride E. Biphasic effects of an-
andamide. Pharmacol Biochem Behav 1998; 59 (2): 347-52
177. Thompson GR, Rosenkrantz H, Schaeppi UH, et al. Compari-
son of acute oral toxicity of cannabinoids in rats, dogs and
monkeys. Toxicol Appl Pharmacol 1973; 25 (3): 363-72
178. Bachs L, Morland H. Acute cardiovascular fatalities following
cannabis use. Forensic Sci Int 2001; 124 (2-3): 200-3
179. Mittleman MA, Lewis RA, Maclure M, et al. Triggering myo-
cardial infarction by marijuana. Circulation 2001; 103 (23):
2805-9
180. Pope HJ. Cannabis, cognition, and residual confounding.
JAMA 2002; 287 (9): 1172-4
181. Solowij N, Stephens RS, Roffman RA, et al. Cognitive func-
tioning of long-term heavy cannabis users seeking treatment.
JAMA 2002; 287 (9): 1123-31
182. Lyketsos CG, Garrett E, Liang KY, et al. Cannabis use and
cognitive decline in persons under 65 years of age. Am J
Epidemiol 1999; 149 (9): 794-800
183. Pope Jr HG, Gruber AJ, Hudson JI, et al. Neuropsychological
performance in long-term cannabis users. Arch Gen Psychia-
try 2001; 58 (10): 909-15
184. Russo E, Mathre ML, Byrne A, et al. Chronic cannabis use in
the compassionate investigational new drug program: an ex-
amination of benefits and adverse effects of legal medical
cannabis. J Cannabis Ther 2002; 2 (1): 3-57
185. Fried PA, Watkinson B, Gray R. Differential effects on cogni-
tive functioning in 9- to 12-year olds prenatally exposed to
cigarettes and marihuana. Neurotoxicol Teratol 1998; 20 (3):
293-306
186. Solowij N, Grenyer BFS. Long term effects of cannabis on psy-
che and cognition. In: Grotenhermen F, Russo E, editors. Can-
nabis and cannabinoids: pharmacology, toxicology, and
therapeutic potential. Binghamton (NY): Haworth Press,
2002: 299-312
187. Mattes RD, Shaw LM, Engelman K. Effects of cannabinoids
(marijuana) on taste intensity and hedonic ratings and salivary
flow of adults. Chem Senses 1994; 19 (2): 125-40
188. Freemon FR. Effects of marihuana on sleeping states. JAMA
1972; 220 (10): 1364-5
189. Lissoni P, Resentini M, Mauri R, et al. Effects of tetrahydro-
cannabinol on melatonin secretion in man. Horm Metab Res
1986; 18 (1): 77-8
190. Wachtel SR, ElSohly MA, Ross SA, et al. Comparison of the
subjective effects of delta (9)-tetrahydrocannabinol and mar-
ijuana in humans. Psychopharmacology 2002; 161 (4): 331-9
191. Hampson RE, Deadwyler SA. Cannabinoids, hippocampal
function and memory. Life Sci 1999; 65: 715-23
192. Heyser CJ, Hampson RE, Deadwyler SA. Effects of delta-9-tet-
rahydrocannabinol on delayed match to sample performance
in rats: alterations in short-term memory associated with
changes in task specific firing of hippocampal cells. J Phar-
macol Exp Ther 1993; 264 (1): 294-307
193. Slikker Jr W, Paule MG, Ali SF, et al. Behavioral, neurochem-
ical and neurohistochemical effects of chronic marijuana
smoke exposure in the nonhuman primate. In: Myrphy L,
Bartke A, editors. Marijuana/cannabinoids: neurobiology and
neurophysiology. Boca Raton (FL): CRC Press, 1992: 219-73
356
Grotenhermen
© Adis International Limited. All rights reserved.
Clin Pharmacokinet 2003; 42 (4)

194. Kelly TH, Foltin RW, Emurian CS, et al. Performance-based
testing for drugs of abuse: dose and time profiles of mari-
juana, amphetamine, alcohol, and diazepam. J Anal Toxicol
1993; 17 (5): 264-72
195. Perez-Reyes M. The psychologic and physiologic effects of
active cannabinoids. In: Nahas G, Sutin KM, Harvey DJ, et
al. Marihuana and medicine. Totowa (NJ): Humana Press,
1999: 245-52
196. Sañudo-Peña MC, Tsou K, Walker JM. Motor actions of can-
nabinoids in the basal ganglia output nuclei. Life Sci 1999;
65: 703-13
197. Pertwee R. In vivo interactions between psychotropic can-
nabinoids and other drugs involving central and peripheral
neurochemical mediators. In: Myrphy L, Bartke A, editors.
Marijuana/cannabinoids: neurobiology and neurophysiol-
ogy. Boca Raton (FL): CRC Press, 1992: 165-218
198. Domino EF. Cannabinoids and the cholinergic system. In:
Nahas G, Sutin KM, Harvey DJ, et al., editors. Marihuana and
medicine. Totowa (NJ): Humana Press, 1999: 223-6
199. Fan P. Cannabinoid agonists inhibit the activation of 5-HT3
receptors in rat nodose ganglion neurons. J Neurophysiol
1995; 73 (2): 907-10
200. Müller-Vahl KR, Kolbe H, Schneider U, et al. Movement dis-
orders. In: Grotenhermen F, Russo E, editors. Cannabis and
cannabinoids: pharmacology, toxicology, and therapeutic po-
tential. Binghamton (NY): Haworth Press, 2002: 205-14
201. Musty RE, Consroe P. Spastic disorders. In: Grotenhermen F,
Russo E, editors. Cannabis and cannabinoids: pharmacology,
toxicology, and therapeutic potential. Binghamton (NY):
Haworth Press, 2002: 195-204
202. Tashkin DP, Levisman JA, Abbasi AS, et al. Short-term effects
of smoked marihuana on left ventricular function in man.
Chest 1977; 72 (1): 20-6
203. Benowitz NL, Jones RT. Cardiovascular effects of prolonged
delta-9-tetrahydrocannabinol ingestion. Clin Pharmacol Ther
1975; 18 (3): 287-97
204. Formukong EA, Evans AT, Evans FJ. The inhibitory effects of
cannabinoids, the active constituents of Cannabis sativa L.,
on human and rabbit platelet aggregation. J Pharm Pharmacol
1989; 41 (10): 705-9
205. O’Leary DS, Block RI, Koeppel JA, et al. Effects of smoking
marijuana on brain perfusion and cognition. Neuro-
psychopharmacology 2002; 26 (6): 802-16
206. Wagner JA, Varga K, Kunos G. Cardiovascular actions of can-
nabinoids and their generation during shock. J Mol Med
1998; 76 (12): 824-36
207. Wagner JA, Jarai Z, Batkai S, et al. Hemodynamic effects of
cannabinoids: coronary and cerebral vasodilation mediated
by cannabinoid CB1 receptors. Eur J Pharmacol 2001; 423
(2-3): 203-10
208. Van Klingeren B, Ten Ham M. Antibacterial activity of Δ9-
tetrahydrocannabinol and cannabidiol. Antonie Van
Leeuwenhoek 1976; 42 (1-2): 9-12
209. Lancz G, Specter S, Brown HK. Suppressive effect of delta-9-
tetrahydrocannabinol on herpes simplex virus infectivity in
vitro. Proc Soc Exp Biol Med 1991; 196 (4): 401-4
210. Pate D. Glaucoma and cannabinoids. In: Grotenhermen F,
Russo E, editors. Cannabis and cannabinoids: pharmacology,
toxicology, and therapeutic potential. Binghamton (NY):
Haworth Press, 2002: 215-24
211. Colasanti BK. A comparison of the ocular and central effects
of delta 9-tetrahydrocannabinol and cannabigerol. J Ocul
Pharmacol 1990; 6 (4): 259-69
212. Murphy L. Hormonal system and reproduction. In: Grotenher-
men F, Russo E, editors. Cannabis and cannabinoids: phar-
macology, toxicology, and therapeutic potential. Binghamton
(NY): Haworth Press, 2002: 289-98
213. Tahir SK, Trogadis JE, Stevens JK, et al. Cytoskeletal organi-
zation following cannabinoid treatment in undifferentiated
and differentiated PC12 cells. Biochem Cell Biol 1992; 70
(10-11): 1159-73
214. De Petrocellis L, Melck D, Palmisano A, et al. The endoge-
nous cannabinoid anandamide inhibits human breast can-
cer cell proliferation. Proc Natl Acad Sci U S A 1998; 95
(14): 8375-80
215. Melck D, De Petrocellis L, Orlando P, et al. Suppression of
nerve growth factor Trk receptors and prolactin receptors by
endocannabinoids leads to inhibition of human breast and
prostate cancer cell proliferation. Endocrinology 2000; 141
(1): 118-26
216. Galve-Roperh I, Sanchez C, Cortes ML, et al. Anti-tumoral
action of cannabinoids: involvement of sustained ceramide
accumulation and extracellular signal-regulated kinase acti-
vation. Nat Med 2000; 6 (3): 313-9
217. Cabral G. Immune system. In: Grotenhermen F, Russo E, edi-
tors. Cannabis and cannabinoids: pharmacology, toxicology,
and therapeutic potential. Binghamton (NY): Haworth Press,
2002: 279-88
218. Melamede R. Possible mechanisms in autoimmune diseases. In:
Grotenhermen F, Russo E, editors. Cannabis and can-
nabinoids: pharmacology, toxicology, and therapeutic poten-
tial. Binghamton (NY): Haworth Press, 2002: 111-22
219. Evans AT, Formukong EA, Evans FJ. Actions of cannabis con-
stituents on enzymes of arachidonate metabolism: anti-in-
flammatory potential. Biochem Pharmacol 1987; 36 (12):
2035-7
220. Sofia RD, Nalepa SD, Harakal JJ, et al. Anti-edema and anal-
gesic properties of Δ9-tetrahydrocannabinol (THC). J Phar-
macol Exp Ther 1973; 186 (3): 646-55
221. Hembree III WC, Nahas GG, Zeidenberg P, et al. Changes in
human spermatozoa associated with high dose marihuana
smoking. Adv Biosci 1978; 22-23: 429-39
222. Chang MC, Berkery D, Schuel R, et al. Evidence for a can-
nabinoid receptor in sea urchin sperm and its role in block-
ade of the acrosome reaction. Mol Reprod Dev 1993; 36
(4): 507-16
223. Williams CM, Kirkham TC. Anandamide induces overeating:
mediation by central cannabinoid (CB1) receptors. Psycho-
pharmacology 1999; 143 (3): 315-7
224. Williams CM, Kirkham TC. Observational analysis of feeding
induced by delta (9)-THC and anandamide. Physiol Behav
2002; 76 (2): 241-50
225. Shook JE, Burks TF. Psychoactive cannabinoids reduce gastro-
intestinal propulsion and motility in rodents. J Pharmacol Exp
Ther 1989; 249 (2): 444-9
226. McCallum RW, Soykan I, Sridhar KR, et al. Delta-9-tetrahy-
drocannabinol delays the gastric emptying of solid food in
humans: a double-blind, randomized study. Aliment Phar-
macol Ther 1999; 13 (1): 77-80
227. Coruzzi G, Adami M, Coppelli G, et al. Inhibitory effect of
the cannabinoid receptor agonist WIN 55,212-2 on penta-
gastrin-induced gastric acid secretion in the anaesthetized
rat. Naunyn Schmiedebergs Arch Pharmacol 1999; 360 (6):
715-8
228. Adami M, Frati P, Bertini S, et al. Gastric antisecretory role and
immunohistochemical localization of cannabinoid receptors
in the rat stomach. Br J Pharmacol 2002; 135 (7): 1598-606
Cannabinoids
357
© Adis International Limited. All rights reserved.
Clin Pharmacokinet 2003; 42 (4)

229. Lemberger L, Crabtree RE, Rowe HM. 11-Hydroxy-Δ9-tetra-
hydrocannabinol: pharmacology, disposition, and metabo-
lism of a major metabolite of marihuana in man. Science
1972; 177 (43): 62-4
230. Perez-Reyes M, Timmons M, Lipton M, et al. Intravenous in-
jection in man of delta-9- tetrahydrocannabinol and 11-OH-
delta-9-tetrahydrocannabinol. Science 1972; 177 (49): 633-5
231. Karler R, Turkanis SA. Different cannabinoids exhibit different
pharmacological and toxicological properties. NIDA Res
Monogr 1987; 79: 96-107
232. Burstein SH, Audette CA, Doyle SA, et al. Antagonism to the
actions of platelet activating factor by a nonpsychoactive can-
nabinoid. J Pharmacol Exp Ther 1989; 251 (2): 531-5
233. Burstein SH. The cannabinoid acids: nonpsychoactive deriva-
tives with therapeutic potential. Pharmacol Ther 1999; 82 (1):
87-96
234. Doyle SA, Burstein SH, Dewey WL, et al. Further studies on
the antinociceptive effects of delta 6-THC-7-oic acid. Agents
Actions 1990; 31 (1-2): 157-63
235. Burstein S, Hunter SA, Latham V, et al. A major metabolite of
delta 1-tetrahydrocannabinol reduces its cataleptic effect in
mice. Experientia 1987; 43 (4): 402-3
236. Zuardi AW, Guimarães FS, Guimarães VMC, et al. Cannabi-
diol: possible therapeutic application. In: Grotenhermen F,
Russo E, editors. Cannabis and cannabinoids: pharmacology,
toxicology, and therapeutic potential. Binghamton (NY):
Haworth Press, 2002: 359-70
237. Karler R, Turkanis SA. The cannabinoids as potential antiepi-
leptics. J Clin Pharmacol 1981; 21 (8-9 Suppl.): 437S-48S
238. Consroe P, Sandyk R, Snider SR. Open label evaluation of can-
nabidiol in dystonic movement disorders. Int J Neurosci 1986;
30 (4): 277-82
239. Parker LA, Mechoulam R, Schlievert C. Cannabidiol, a non-
psychoactive component of cannabis and its synthetic
dimethylheptyl homolog suppress nausea in an experimental
model with rats. Neuroreport 2002; 13 (5): 567-70
240. Malfait AM, Gallily R, Sumariwalla PF, et al. The non-
psychoactive cannabis constituent cannabidiol is an oral anti-
arthritic therapeutic in murine collagen-induced arthritis. Proc
Natl Acad Sci U S A 2000; 97 (17): 9561-6
241. Colasanti BK, Brown RE, Craig CR. Ocular hypotension, ocu-
lar toxicity, and neurotoxicity in response to marihuana ex-
tract and cannabidiol. Gen Pharmacol 1984; 15 (6): 479-84
242. Baek SH, Kim YO, Kwag JS, et al. Boron trifluoride etherate
on silica-A modified Lewis acid reagent (VII): antitumor ac-
tivity of cannabigerol against human oral epitheloid carci-
noma cells. Arch Pharm Res 1998; 21 (3): 353-6
243. Fride E, Barg J, Levy R, et al. Low doses of anandamides inhibit
pharmacological effects of delta 9-tetrahydrocannabinol. J
Pharmacol Exp Ther 1995; 272 (2): 699-707
244. Archer RA, Stark P, Lemberger L. Nabilone. In: Mechoulam R,
editor. Cannabinoids as therapeutic agents. Boca Raton: CRC
Press, 1986: 85-103
245. Little PJ, Compton DR, Mechoulam R, et al. Stereochemical
effects of 11-OH-Δ8-THC-dimethylheptyl in mice and dogs.
Pharmacol Biochem Behav 1989; 32: 661-6
246. Ottani A, Giuliani D. Hu 210: a potent tool for investigations of
the cannabinoid system. CNS Drug Rev 2001; 7 (2): 131-45
247. Titishov N, Mechoulam R, Zimmerman AM. Stereospecific ef-
fects of (–)- and (+)-7-hydroxy-delta-6-tetrahydrocannabi-
nol-dimethylheptyl on the immune system of mice.
Pharmacology 1989; 39 (6): 337-49
248. Mechoulam R, Shohami E. HU-211: cannabinoid neuroprotec-
tive agent. In: Grotenhermen F, Russo E, editors. Cannabis
and cannabinoids: pharmacology, toxicology, and therapeutic
potential. Binghamton (NY): Haworth Press, 2002: 389-400
249. Burstein S. Therapeutic potential of ajulemic acid (CT3). In:
Grotenhermen F, Russo E, editors. Cannabis and can-
nabinoids: pharmacology, toxicology, and therapeutic poten-
tial. Binghamton (NY): Haworth Press, 2002: 381-8
250. Jain AK, Ryan JR, McMahon FG, et al. Evaluation of intramus-
cular levonantrodol and placebo in acute postoperative pain.
J Clin Pharmacol 1981; 21 (8-9 Suppl.): 320S-6S
251. Citron ML, Herman TS, Vreeland F, et al. Antiemetic efficacy
of levonantradol compared to delta-9-tetrahydrocannabinol
for chemotherapy-induced nausea and vomiting. Cancer Treat
Rep 1985; 69: 109-12
252. Lucraft HH, Palmer MK. Randomized clinical trial of
levonantradol and chlorpromazine in the prevention of radio-
therapy-induced vomiting. Clin Radiol 1982; 33 (6): 621-2
253. Showalter VM, Compton DR, Martin BR, et al. Evaluation of
binding in a transfected cell line expressing a peripheral can-
nabinoid receptor (CB2): identification of cannabinoid recep-
tor subtype selective ligands. J Pharmacol Exp Ther 1996; 278
(3): 989-99
254. Melvin LS, Milne GM, Johnson MR, et al. Structure-activity
relationships for cannabinoid receptor-binding and analgesic
activity: studies of bicyclic cannabinoid analogs. Mol Phar-
macol 1993; 44 (5): 1008-15
255. Beltramo M, Stella N, Calignano A, et al. Functional role of
high-affinity anandamide transport, as revealed by selective
inhibition. Science 1997; 277 (5329): 1094-7
256. Jaggar SI, Hasnie FS, Sellaturay S, et al. The anti-hyperalgesic
actions of the cannabinoid anandamide and the putative CB2
receptor agonist palmitoylethanolamide in visceral and so-
matic inflammatory pain. Pain 1998; 76 (1-2): 189-99
257. Terranova J-P, Storme J-J, Lafon N, et al. Improvement of
memory in rodents by the selective CB1 cannabinoid receptor
antagonist, SR 141716. Psychopharmacology 1996; 126:
165-72
258. Huestis MA, Gorelick DA, Heishman SJ, et al. Blockade of
effects of smoked marijuana by the CB1-selective can-
nabinoid receptor antagonist SR141716. Arch Gen Psychiatry
2001; 58 (4): 322-8
259. Di Marzo V, Hill MP, Bisogno T, et al. Enhanced levels of
endogenous cannabinoids in the globus pallidus are associ-
ated with a reduction in movement in an animal model of
Parkinson’s disease. FASEB J 2000; 14 (10): 1432-8
260. Müller-Vahl KR, Schneider U, Emrich HM. Nabilone increases
choreatic movements in Huntington’s disease. Mov Disord
1999; 14 (6): 1038-40
261. Romero J, Garcia-Palomero E, Castro JG, et al. Effects of
chronic exposure to Δ9-tetrahydrocannabinol on cannabinoid
receptor binding and mRNA levels in several rat brain re-
gions. Brain Res Mol Brain Res 1997; 46 (1-2): 100-8
262. Jones RT, Benowitz N, Bachman J. Clinical studies of cannabis
tolerance and dependence. Ann N Y Acad Sci 1976; 282:
221-39
263. Stefanis C. Biological aspects of cannabis use. NIDA Res
Monogr 1978; 19: 149-78
264. Bass CE, Martin BR. Time course for the induction and main-
tenance of tolerance to Delta (9)-tetrahydrocannabinol in
mice. Drug Alcohol Depend 2000; 60 (2): 113-9
265. Luthra YK, Esber HJ, Lariviere DM, et al. Assessment of tol-
erance to immunosuppressive activity of delta 9-tetrahydro-
cannabinol in rats. J Immunopharmacol 1980; 2 (2): 245-56
358
Grotenhermen
© Adis International Limited. All rights reserved.
Clin Pharmacokinet 2003; 42 (4)

266. Miczek KA, Dixit BN. Behavioral and biochemical effects of
chronic delta 9-tetrahydrocannabinol in rats. Psychopharma-
cology (Berl) 1980; 67 (2): 195-202
267. Smith CG, Almirez RG, Berenberg J, et al. Tolerance develops
to the disruptive effects of delta 9-tetrahydrocannabinol on
primate menstrual cycle. Science 1983; 219 (4591): 1453-5
268. Di Marzo V, Berrendero F, Bisogno T, et al. Enhancement of
anandamide formation in the limbic forebrain and reduction
of endocannabinoid contents in the striatum of Δ9-tetrahydro-
cannabinol-tolerant rats. J Neurochem 2000; 74 (4): 1627-35
269. Rubino T, Vigano D, Massi P, et al. Changes in the cannabinoid
receptor binding, G protein coupling, and cyclic AMP cas-
cade in the CNS of rats tolerant to and dependent on the
synthetic cannabinoid compound CP55,940. J Neurochem
2000; 75 (5): 2080-6
270. Abood ME, Sauss C, Fan F, et al. Development of behavioral
tolerance to delta 9-THC without alteration of cannabinoid
receptor binding or mRNA levels in whole brain. Pharmacol
Biochem Behav 1993; 46 (3): 575-9
271. Rubino T, Vigano D, Costa B, et al. Loss of cannabinoid-stim-
ulated guanosine 5′-O- (3-[35S]thiotriphosphate) binding
without receptor down-regulation in brain regions of an-
andamide-tolerant rats. J Neurochem 2000; 75 (6): 2478-84
272. Georgotas A, Zeidenberg P. Observations on the effects of four
weeks of heavy marihuana smoking on group interaction and
individual behavior. Compr Psychiatry 1979; 20 (5): 427-32
273. Anthony JC, Warner LA, Kessler RC. Comparative epidemiol-
ogy of dependence on tobacco, alcohol, controlled sub-
stances, and inhalants: basic findings from the National
Comorbidity Survey. Exp Clin Psychopharmacol 1994; 2:
244-68
274. Kleiber D, Soellner R, Tossmann P. Cannabiskonsum in der
Bundesrepublik
Deutschland:
Entwicklungstendenzen,
Konsummuster und Einflußfaktoren. Bonn: Federal Ministry
of Health, 1997
275. Roques B. Problemes posées par la dangerosité des drogues.
Rapport du professeur Bernhard Roques au Secrétaire d’Etat
à la Santé. Paris, 1998
276. Calhoun SR, Galloway GP, Smith DE. Abuse potential of
dronabinol (Marinol®). J Psychoactive Drugs 1998; 30 (2):
187-96
277. British Medical Association. Therapeutic uses of cannabis.
Amsterdam: Harwood Academic Publishers, 1997
278. Grinspoon L, Bakalar JB. Marihuana, the forbidden medicine.
New Haven (CT): Yale University Press, 1993
279. Grotenhermen F. Review of therapeutic effects. In: Grotenher-
men F, Russo E, editors. Cannabis and cannabinoids: phar-
macology, toxicology, and therapeutic potential. Binghamton
(NY): Haworth Press, 2002: 123-42
280. Mathre ML, editor. Cannabis in medical practice: a legal, his-
torical and pharmacological overview of the therapeutic use
of marijuana. Jefferson (NC): McFarland & Co, 1997
281. Mechoulam R, editor. Cannabinoids as therapeutic agents.
Boca Raton: CRC Press, 1986
282. Dansak DA. As an antiemetic and appetite stimulant in cancer
patients. In: Mathre ML, editor. Cannabis in medical practice:
a legal, historical and pharmacological overview of the ther-
apeutic use of marijuana. Jefferson (NC): McFarland & Co,
1997: 69-83
283. Lane M, Vogel CL, Ferguson J, et al. Dronabinol and pro-
chlorperazine in combination for treatment of cancer chemo-
therapy-induced nausea and vomiting. J Pain Symptom
Manage 1991; 6 (6): 352-9
284. Sallan SE, Cronin C, Zelen M, et al. Antiemetics in patients
receiving chemotherapy for cancer: a randomized compari-
son of delta-9-tetrahydrocannabinol and prochlorperazine. N
Engl J Med 1980; 302 (3): 135-8
285. Beal JE, Olson R, Lefkowitz L, et al. Long-term efficacy and
safety of dronabinol for acquired immunodeficiency syn-
drome-associated anorexia. J Pain Symptom Manage 1997;
14 (1): 7-14
286. Plasse TF, Gorter RW, Krasnow SH, et al. Recent clinical ex-
perience with dronabinol. Pharmacol Biochem Behav 1991;
40 (3): 695-700
287. Beal JE, Olson R, Laubenstein L, et al. Dronabinol as a treat-
ment for anorexia associated with weight loss in patients with
AIDS. J Pain Symptom Manage 1995; 10 (2): 89-97
288. Jatoi A, Windschitl HE, Loprinzi CL, et al. Dronabinol versus
megestrol acetate versus combination therapy for cancer-
associated anorexia: a North Central Cancer Treatment
Group study. J Clin Oncol 2002; 20 (2): 567-73
289. Soderpalm AH, Schuster A, de Wit H. Antiemetic efficacy of
smoked marijuana: subjective and behavioral effects on nau-
sea induced by syrup of ipecac. Pharmacol Biochem Behav
2001; 69 (3-4): 343-50
290. Maurer M, Henn V, Dittrich A, et al. Delta-9-tetrahydrocannab-
inol shows antispastic and analgesic effects in a single case
double-blind trial. Eur Arch Psychiatry Neurol Sci 1990; 240
(1): 1-4
291. Petro DJ. Marihuana as a therapeutic agent for muscle spasm
or spasticity. Psychosomatics 1980; 21 (1): 81-5
292. Killestein J, Hoogervorst EL, Reif M, et al. Safety, tolerability,
and efficacy of orally administered cannabinoids in MS. Neu-
rology 2002; 58 (9): 1404-7
293. Martyn CN, Illis LS, Thom J. Nabilone in the treatment of
multiple sclerosis [letter]. Lancet 1995; 345 (8949): 579
294. Meinck HM, Schonle PW, Conrad B. Effect of cannabinoids
on spasticity and ataxia in multiple sclerosis. J Neurol 1989;
236 (2): 120-2
295. Petro DJ, Ellenberger Jr C. Treatment of human spasticity with
delta 9-tetrahydrocannabinol. J Clin Pharmacol 1981; 21 (8-9
Suppl.): 413S-6S
296. Ungerleider JT, Andyrsiak T, Fairbanks L, et al. Delta-9-THC
in the treatment of spasticity associated with multiple sclero-
sis. Adv Alcohol Subst Abuse 1987; 7 (1): 39-50
297. Elsner F, Radbruch L, Sabatowski R. Tetrahydrocannabinol zur
Therapie chronischer Schmerzen [Tetrahydrocannabinol for
treatment of chronic pain]. Schmerz 2001; 15 (3): 200-4
298. Notcutt W, Price M, Miller R, et al. Medicinal cannabis extracts
in chronic pain: (2) comparison of two patients with back pain
and sciatica. Congress on Cannabis and the Cannabinoids.
Cologne: International Association for Cannabis as Medi-
cine, 2001
299. Notcutt W, Price M, Miller R, et al. Medicinal cannabis extracts
in chronic pain: (3) comparison of two patients with multiple
sclerosis. Congress on Cannabis and the Cannabinoids. Co-
logne: International Association for Cannabis as Medicine,
2001
300. Noyes Jr R, Brunk SF, Avery DAH, et al. The analgesic prop-
erties of delta-9-tetrahydrocannabinol and codeine. Clin
Pharmacol Ther 1975; 18 (1): 84-9
301. Noyes Jr R, Brunk SF, Baram DA, et al. Analgesic effect of
delta-9-tetrahydrocannabinol. J Clin Pharmacol 1975; 15 (2-
3): 139-43
302. Clifford DB. Tetrahydrocannabinol for tremor in multiple scle-
rosis. Ann Neurol 1983; 13 (6): 669-71
Cannabinoids
359
© Adis International Limited. All rights reserved.
Clin Pharmacokinet 2003; 42 (4)

303. Fox SH, Kellett M, Moore AP, et al. Randomised, double-blind,
placebo-controlled trial to assess the potential of cannabinoid
receptor stimulation in the treatment of dystonia. Mov Disord
2002; 17 (1): 145-9
304. Hemming M, Yellowlees PM. Effective treatment of
Tourette’s syndrome with marijuana. J Psychopharmacol
1993; 7: 389-91
305. Müller-Vahl KR, Schneider U, Kolbe H, et al. Treatment of
Tourette’s syndrome with delta-9-tetrahydrocannabinol [let-
ter]. Am J Psychiatry 1999; 156 (3): 495
306. Müller-Vahl KR, Schneider U, Koblenz A, et al. Treatment of
Tourette’s syndrome with Δ9-tetrahydrocannabinol (THC): a
randomized crossover trial. Pharmacopsychiatry 2002; 35 (2):
57-61
307. Sandyk R, Awerbuch G. Marijuana and Tourette’s syndrome
[letter]. J Clin Psychopharmacol 1998; 8: 844
308. Sieradzan KA, Fox SH, Hill M, et al. Cannabinoids reduce levo-
dopa-induced dyskinesia in Parkinson’s disease: a pilot study.
Neurology 2001; 57 (11): 2108-11
309. Hartley JP, Nogrady SG, Seaton A. Bronchodilator effect of
delta1-tetrahydrocannabinol. Br J Clin Pharmacol 1978; 5 (6):
523-5
310. Tashkin DP, Shapiro BJ, Frank IM. Acute effects of smoked
marijuana and oral Δ9-tetrahydrocannabinol on specific air-
way conductance in asthmatic subjects. Am Rev Respir Dis
1974; 109 (4): 420-8
311. Crawford WJ, Merritt JC. Effects of tetrahydrocannabinol on
arterial and intraocular hypertension. Int J Clin Pharmacol
Biopharm 1979; 17 (5): 191-6
312. Hepler RS, Frank IR. Marihuana smoking and intraocular pres-
sure [letter]. JAMA 1971; 217 (10): 1392
313. Hepler RS, Petrus RJ. Experiences with administration of ma-
rihuana to glaucoma patients. In: Cohen S, Stillman RC, edi-
tors. The therapeutic potential of marihuana. New York:
Plenum Medical Book, 1976: 63-75
314. Merritt JC, Crawford WJ, Alexander PC, et al. Effect of mari-
huana on intraocular and blood pressure in glaucoma. Oph-
thalmology 1980; 87 (3): 222-8
315. Schnelle M, Grotenhermen F, Reif M, et al. Ergebnisse einer
standardisierten Umfrage zur medizinischen Verwendung
von Cannabisprodukten im deutschen Sprachraum, [Results
of a standardized survey on the medical use of cannabis
products in the German-speaking area]. Forsch Komple-
mentarmed [Res Complementary Med] 1999: 36
316. Gordon E, Devinsky O. Alcohol and marijuana: effects on epi-
lepsy and use by patients with epilepsy. Epilepsia 2001; 42
(10): 1266-72
317. Gilson I, Busalacchi M. Marijuana for intractable hiccups [let-
ter]. Lancet 1998; 351 (9098): 267
318. Grinspoon L, Bakalar JB. The use of cannabis as a mood stabi-
lizer in bipolar disorder: anecdotal evidence and the need for
clinical research. J Psychoactive Drugs 1998; 30 (2): 171-7
319. Mikuriya TH. Cannabis substitution: an adjunctive therapeutic
tool in the treatment of alcoholism. Med Times 1970; 98 (4):
187-91
320. Volicer L, Stelly M, Morris J, et al. Effects of dronabinol on
anorexia and disturbed behavior in patients with Alzheimer’s
disease. Int J Geriatr Psychiatry 1997; 12 (9): 913-9
321. Ralevic V, Kendall DA. Cannabinoid inhibition of capsaicin-
sensitive sensory neurotransmission in the rat mesenteric ar-
terial bed. Eur J Pharmacol 2001; 418 (1-2): 117-25
322. Jacobsson SO, Wallin T, Fowler CJ. Inhibition of rat C6 glioma
cell proliferation by endogenous and synthetic cannabinoids:
relative involvement of cannabinoid and vanilloid receptors.
J Pharmacol Exp Ther 2001; 299 (3): 951-9
323. Guzman M, Sanchez C, Galve-Roperh I. Control of the cell
survival/death decision by cannabinoids. J Mol Med 2001; 78
(11): 613-25
324. Izzo AA, Pinto L, Borrelli F, et al. Central and peripheral can-
nabinoid modulation of gastrointestinal transit in physiologi-
cal states or during the diarrhoea induced by croton oil. Br J
Pharmacol 2000; 129 (8): 1627-32
325. Calignano A, Katona I, Desarnaud F, et al. Bidirectional control
of airway responsiveness by endogenous cannabinoids. Na-
ture 2000; 408 (6808): 96-101
326. Carley DW, Paviovic S, Janelidze M, et al. Functional role for
cannabinoids in respiratory stability during sleep. Sleep 2002;
25 (4): 391-8
327. Pryor GT, Husain S, Mitoma C. Acute and subacute interactions
between delta-9-tetrahydrocannabinol and other drugs in the
rat. Ann N Y Acad Sci 1976; 281: 171-89
328. Kosel BW, Aweeka FT, Benowitz NL, et al. The effects of
cannabinoids on the pharmacokinetics of indinavir and
nelfinavir. AIDS 2002; 16 (4): 543-50
329. Zullino DF, Delessert D, Eap CB, et al. Tobacco and cannabis
smoking cessation can lead to intoxication with clozapine or
olanzapine. Int Clin Psychopharmacol 2002; 17 (3): 141-3
330. Hollister LE. Interactions of marihuana and Δ9-THC with other
drugs. In: Nahas G, Sutin KM, Harvey DJ, et al., editors.
Marihuana and medicine. Totowa (NJ): Humana Press, 1999:
273-7
331. Sutin KM, Nahas GG. Physiological and pharmacological in-
teractions of marihuana (Δ9-THC) with drugs and anesthetics.
In: Nahas G, Sutin KM, Harvey DJ, et al., editors. Marihuana
and medicine. Totowa (NJ): Humana Press, 1999: 253-71
332. Brody S, Preut R. Cannabis, tobacco, and caffeine use modify
the blood pressure reactivity protection of ascorbic acid. Phar-
macol Biochem Behav 2002; 72 (4): 811-6
333. Welch SP, Eads M. Synergistic interactions of endogenous op-
ioids and cannabinoid systems. Brain Res 1999; 848 (1-2):
183-90
334. Koe BK, Milne GM, Weissman A, et al. Enhancement of brain
[3H]flunitrazepam binding and analgesic activity of synthetic
cannabimimetics. Eur J Pharmacol 1985; 109 (2): 201-12
335. Moss DE, Manderscheid PZ, Montgomery SP, et al. Nicotine
and cannabinoids as adjuncts to neuroleptics in the treatment
of Tourette syndrome and other motor disorders. Life Sci
1989; 44 (21): 1521-5
336. Perez-Reyes M, Burstein SH, White WR, et al. Antagonism of
marihuana effects by indomethacin in humans. Life Sci 1991;
48 (6): 507-15
337. Green K, Kearse EC, McIntyre OL. Interaction between delta-
9-tetrahydrocannabinol and indomethacin. Ophthalmic Res
2001; 33 (4): 217-20
338. Mechoulam R, Hanus L, Fride E. Towards cannabinoid drugs:
revisited. Prog Med Chem 1998; 35: 199-243
339. Bisogno T, Hanus L, De Petrocellis L, et al. Molecular targets
for cannabidiol and its synthetic analogues: effect on vanilloid
VR1 receptors and on the cellular uptake and enzymatic hy-
drolysis of anandamide. Br J Pharmacol 2001; 134 (4): 845-52
Correspondence and offprints: Dr Franjo Grotenhermen,
Nova-Institut, Goldenbergstrasse 2, 50254 Hürth, Ger-
many.
E-mail: franjo.grotenhermen@nova-institut.de
360
Grotenhermen
© Adis International Limited. All rights reserved.
Clin Pharmacokinet 2003; 42 (4)